var title_f20_10_20640="Atlantoaxial anatomy";
var content_f20_10_20640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Upper cervical vertebrae, assembled: posterosuperior view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atlantoaxial anatomy. The first two cervical vertebrae are specialized bones that function as an important unit. The atlas (C1) articulates with the occiput of the skull superiorly and with the axis (C2) inferiorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_10_20640=[""].join("\n");
var outline_f20_10_20640=null;
var title_f20_10_20641="Posterior shoulder capsule stretch";
var content_f20_10_20641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Posterior shoulder capsule stretch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 209px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the elbow bent to 90 degrees, extend your shoulder until your forearm is parallel to the ground and directly in front of you. Using the opposite hand, grasp behind your elbow and gradually pull your arm across your body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_10_20641=[""].join("\n");
var outline_f20_10_20641=null;
var title_f20_10_20642="Contents: Gastrointestinal cancer";
var content_f20_10_20642=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/12/3278\">",
"       Gastroenterology and Hepatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Gastrointestinal cancer",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Gastrointestinal cancer",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Anus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/33/1562\">",
"           Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/29/12761\">",
"           Classification and epidemiology of anal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/54/38762\">",
"           Clinical features, staging, and treatment of anal cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Appendix",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/14/36074\">",
"           Cancer of the appendix and pseudomyxoma peritonei",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/60/969\">",
"           Clinical characteristics of carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9206\">",
"           Clinical features of the carcinoid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/30/43496\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/32/6665\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/46/39658\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39897\">",
"           Treatment and surveillance of non-metastatic carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/31/16888\">",
"           Treatment of the carcinoid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Colon and rectum",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/55/30586\">",
"           Adjuvant chemotherapy for resected stage II colon cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/51/11066\">",
"           Adjuvant therapy for resected colon cancer in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/51/4922\">",
"           Adjuvant therapy for resected rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/44/34506\">",
"           Adjuvant therapy for resected stage III (node-positive) colon cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/62/32746\">",
"           Approach to the patient with colonic polyps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/60/969\">",
"           Clinical characteristics of carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/59/19386\">",
"           Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/63/9206\">",
"           Clinical features of the carcinoid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/39/17016\">",
"           Clinical manifestations and diagnosis of familial adenomatous polyposis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/33/17946\">",
"           Clinical manifestations, diagnosis, and staging of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/7/25722\">",
"           Colorectal cancer surveillance in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/25/42394\">",
"           Colorectal cancer: Epidemiology, risk factors, and protective factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/49/36632\">",
"           Computed tomographic colonography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/8/11400\">",
"           Diagnosis of the carcinoid syndrome and tumor localization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/14/16618\">",
"           Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/29/19930\">",
"           Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/5/29783\">",
"           Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/55/41850\">",
"           Management of potentially resectable colorectal cancer liver metastases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/30/43496\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/32/6665\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/46/39658\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/33/30234\">",
"           Molecular genetics of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/22/42346\">",
"           Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/36/28234\">",
"           Nonsurgical local treatment strategies for colorectal cancer liver metastases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/6/37990\">",
"           Overview of Peutz-Jeghers syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/15/38137\">",
"           Overview of surgical procedures for resectable primary rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/49/30489\">",
"           Overview of the management of primary colon cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/34/41514\">",
"           Pathology and prognostic determinants of colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/9/3224\">",
"           Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/57/6041\">",
"           Pretreatment local staging evaluation for rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/10/37034\">",
"           Screening for colorectal cancer: Strategies in patients at average risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/41/9881\">",
"           Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/61/28634\">",
"           Surveillance after colorectal cancer resection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/32/44554\">",
"           Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/20/21833\">",
"           Systemic chemotherapy for metastatic colorectal cancer: General principles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/1/44058\">",
"           Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/31/41466\">",
"           Therapy for metastatic colorectal cancer in elderly patients and those with a poor performance status",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39897\">",
"           Treatment and surveillance of non-metastatic carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/37/11866\">",
"           Treatment of locally advanced unresectable or recurrent rectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/31/16888\">",
"           Treatment of the carcinoid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Esophagus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/34/33321\">",
"           Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/10/44202\">",
"           Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/45/7898\">",
"           Diagnosis and staging of esophageal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/1/42006\">",
"           Endoscopic palliation of esophageal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/13/1242\">",
"           Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/35/35386\">",
"           Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/31/32250\">",
"           Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/7/34938\">",
"           Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/25/30106\">",
"           Management of locally advanced unresectable esophageal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/60/20426\">",
"           Management of superficial esophageal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/51/39738\">",
"           Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/12/8391\">",
"           Pathogenesis of Barrett's esophagus and its malignant transformation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/31/39418\">",
"           Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/30/34282\">",
"           Surgical oncologic principles for management of resectable esophageal cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatobiliary",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/24/43399\">",
"           Adjuvant treatment for localized, potentially resectable gallbladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/52/43848\">",
"           Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/37/3674\">",
"           Ampullary carcinoma: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/10/34986\">",
"           Clinical features and diagnosis of primary hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/43/40633\">",
"           Clinical manifestations and diagnosis of cholangiocarcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/22/19816\">",
"           Endoscopic methods for the diagnosis of pancreatobiliary neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/38/25194\">",
"           Epidemiology and etiologic associations of hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/54/43881\">",
"           Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/46/15082\">",
"           Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/32/36362\">",
"           Liver transplantation for hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/29/21978\">",
"           Management of potentially resectable hepatocellular carcinoma: Prognosis, role of neoadjuvant and adjuvant therapy, and posttreatment surveillance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/18/36138\">",
"           Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/9/41114\">",
"           Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/3/43063\">",
"           Overview of treatment approaches for hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/24/25992\">",
"           Staging and prognostic factors in hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/6/14442\">",
"           Surgical management of potentially resectable hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/32/10761\">",
"           Systemic therapy for advanced cholangiocarcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39898\">",
"           Systemic treatment for advanced hepatocellular carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/11/33977\">",
"           Treatment of advanced, unresectable gallbladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/33/25114\">",
"           Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/58/34728\">",
"           Treatment options for locally advanced cholangiocarcinoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/63/39928\">",
"           Malignancy-related ascites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/21/17754\">",
"           Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/48/35593\">",
"           Malignant peritoneal mesothelioma: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/53/29530\">",
"           PTEN hamartoma tumor syndrome, including Cowden syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pancreas",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/33/22042\">",
"           Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/12/39114\">",
"           Chemotherapy for advanced exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/57/18330\">",
"           Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/10/14504\">",
"           Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/40/41610\">",
"           Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/56/1929\">",
"           Endoscopic ultrasound in the staging of exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/13/27866\">",
"           Epidemiology and risk factors for exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/20/17735\">",
"           Exocrine pancreatic cancer: Palliation of symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/57/31640\">",
"           Glucagonoma and the glucagonoma syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/30/12777\">",
"           Insulinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/51/6968\">",
"           Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/37/33370\">",
"           Management of locally advanced and borderline resectable exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/30/43496\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/32/6665\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/46/39658\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/12/13513\">",
"           Molecular pathogenesis of exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/27/44472\">",
"           Pathology of exocrine pancreatic neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/40/6794\">",
"           Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/34/3623\">",
"           Somatostatinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/34/8746\">",
"           Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/59/16311\">",
"           The VIPoma syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Small bowel",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/34/33321\">",
"           Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/60/969\">",
"           Clinical characteristics of carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/32/8714\">",
"           Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/43/10937\">",
"           Diagnosis and staging of small bowel neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/8/11400\">",
"           Diagnosis of the carcinoid syndrome and tumor localization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/13/1242\">",
"           Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/35/35386\">",
"           Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/31/18938\">",
"           Epidemiology, clinical features, and types of small bowel neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/7/34938\">",
"           Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/53/3930\">",
"           Management of gastrointestinal lymphomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/30/43496\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/32/6665\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/46/39658\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39897\">",
"           Treatment and surveillance of non-metastatic carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/8/21642\">",
"           Treatment of small bowel neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/31/16888\">",
"           Treatment of the carcinoid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Stomach",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/34/33321\">",
"           Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/38/11882\">",
"           Adjuvant and neoadjuvant treatment of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/36/2634\">",
"           Association between Helicobacter pylori infection and gastrointestinal malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/60/969\">",
"           Clinical characteristics of carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/36/11850\">",
"           Clinical features, diagnosis, and staging of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/32/8714\">",
"           Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/8/11400\">",
"           Diagnosis of the carcinoid syndrome and tumor localization",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/10/37033\">",
"           Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/46/4842\">",
"           Early gastric cancer: Treatment, natural history, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/13/1242\">",
"           Endoscopic ultrasound for the characterization of subepithelial lesions of the upper gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/35/35386\">",
"           Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/19/2361\">",
"           Gastric polyps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/15/2296\">",
"           Hereditary diffuse gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/15/33018\">",
"           Invasive gastric cancer: Surgery and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/56/19333\">",
"           Local palliation for advanced gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/7/34938\">",
"           Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/53/3930\">",
"           Management of gastrointestinal lymphomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/30/43496\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/32/6665\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/46/39658\">",
"           Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/26/33194\">",
"           Pathology and molecular pathogenesis of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/38/618\">",
"           Risk factors for gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/52/6983\">",
"           Screening and prevention of gastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39897\">",
"           Treatment and surveillance of non-metastatic carcinoid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/31/16888\">",
"           Treatment of the carcinoid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-880E641AD2-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f20_10_20642=[""].join("\n");
var outline_f20_10_20642=null;
var title_f20_10_20643="Chondroitin sulfate-sodium hyaluronate: Patient drug information";
var content_f20_10_20643=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chondroitin sulfate-sodium hyaluronate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/47/36594?source=see_link\">",
"     see \"Chondroitin sulfate-sodium hyaluronate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DisCoVisc&reg;;",
"     </li>",
"     <li>",
"      Viscoat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691303",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used for eye surgeries.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701797",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chondroitin sulfate, sodium hyaluronate, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701630",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to birds or eggs, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More eye pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the eye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12334 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_10_20643=[""].join("\n");
var outline_f20_10_20643=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151056\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017463\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017462\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017467\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017468\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017470\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017465\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017466\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017471\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017472\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/47/36594?source=related_link\">",
"      Chondroitin sulfate-sodium hyaluronate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_10_20644="Entacapone: Patient drug information";
var content_f20_10_20644=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Entacapone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38501?source=see_link\">",
"     see \"Entacapone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Comtan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Comtan&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Entacapone;",
"     </li>",
"     <li>",
"      Teva-Entacapone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to entacapone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking monoamine oxidase inhibitors (eg, isocarboxazid, phenelzine, and tranylcypromine) talk with your doctor. Taking both at the same time could cause risky high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Extra muscle action or slow movement. Levodopa/carbidopa dose may need to be changed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697957",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of urine to brown or orange.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698545",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a diary of your signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12421 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-85B74C0F79-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_10_20644=[""].join("\n");
var outline_f20_10_20644=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165167\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165168\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014293\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014292\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014297\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014298\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014300\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014295\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014296\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014301\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014302\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38501?source=related_link\">",
"      Entacapone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_10_20645="Methyldopa: Pediatric drug information";
var content_f20_10_20645=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methyldopa: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"    see \"Methyldopa: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/6/29797?source=see_link\">",
"    see \"Methyldopa: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F195033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Methyldopa&reg;;",
"     </li>",
"     <li>",
"      Nu-Medopa",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Inhibitors, Central",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"      see \"Methyldopa: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial: 10 mg/kg/day in 2-4 divided doses; increase every 2 days as needed to maximum dose of 65 mg/kg/day; do not exceed 3 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Initial: 2-4 mg/kg/dose; if response is not seen within 4-6 hours, may increase to 5-10 mg/kg/dose; administer doses every 6-8 hours; maximum daily dose: 65 mg/kg or 3 g, whichever is less",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial: 250 mg 2-3 times/day; increase every 2 days as needed; usual dose 500 mg to 2 g daily in 2-4 divided doses; maximum dose: 3 g/day; usual dosage range (JNC 7): 250-1000 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 250-1000 mg every 6-8 hours; maximum dose: 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: Administer normal dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer normal dose every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer normal dose every 12-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 50 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be administered without regard to food; administer new dosage increases in the evening to minimize sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: Infuse I.V. dose slowly over 30-60 minutes at a concentration &le;10 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F195088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, sodium bicarbonate 5%, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Esmolol, heparin, meperidine, morphine, theophylline.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     TPN.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of moderate to severe hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Methyldopa may be confused with L-dopa, levodopa",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - low; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F195087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina pectoris aggravation, bradycardia, carotid sinus hypersensitivity prolonged, heart failure, myocarditis, orthostatic hypotension, paradoxical pressor response (I.V. use), pericarditis, peripheral edema, symptoms of cerebrovascular insufficiency, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Bell&rsquo;s palsy, dizziness, drug fever, headache, lightheadedness, mental acuity decreased, mental depression, nightmares, parkinsonism, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breast enlargement, gynecomastia, hyperprolactinemia, lactation, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, colitis, constipation, diarrhea, flatulence, nausea, pancreatitis, sialadenitis, sore or &ldquo;black&rdquo; tongue, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bone marrow suppression, eosinophilia, granulocytopenia, hemolytic anemia; positive tests for ANA, LE cells, rheumatoid factor, Coombs test (positive); leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Abnormal LFTs, liver disorders (hepatitis), jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, choreoathetosis, myalgia, paresthesias, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: SLE-like syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methyldopa or any component; liver disease, pheochromocytoma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and adjust dose in patients with renal dysfunction; active metabolite may accumulate in uremia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection contains sodium bisulfite which may cause allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of COMT",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Alpha2-Antagonist): May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If these combinations cannot be avoided, monitor for decreased effects of alpha2-agonists if an alpha2-antagonist is initiated/dose increased, or increased effects if an alpha2-antagonist is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Methyldopa may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Methyldopa.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Methyldopa may enhance the adverse/toxic effect of Lithium. This may occur without notable changes in serum lithium concentrations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Methyldopa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Methyldopa. Management: Consider separating doses of these products by 2 or more hours to minimize this interaction; however, the success of this action appears limited.  Monitor for decreased therapeutic effects of methyldopa with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1053955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid natural licorice (causes sodium and water retention and increases potassium loss); dietary requirements for vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and folate may be increased with high doses of methyldopa",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (injectable) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F195016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Methyldopa crosses the placenta and appears in cord blood. Methyldopa is considered an appropriate agent for the treatment of hypertension in pregnancy (ACOG, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, CBC with differential, hemoglobin, hematocrit, Coombs' test [direct], liver enzymes",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates inhibitory alpha-adrenergic receptors via alpha-methylnorepinephrine (false transmitter); this results in a decreased sympathetic outflow to the heart, kidneys, and peripheral vasculature; may decrease plasma renin activity",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1053950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypotensive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Oral, I.V.: Single-dose: Within 3-6 hours; multiple-dose: 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Single-dose: 12-24 hours; multiple-dose: 1-2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 10-16 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: &sim;50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses placenta; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the intestine and the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 10-20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &sim;70% of systemic dose eliminated in urine as drug and metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Slightly dialyzable (5% to 20%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/6/29797?source=see_link\">",
"      see \"Methyldopa: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; rise slowly from prolonged sitting or lying position; may cause urine to turn red or brown; notify physician of unexplained prolonged general tiredness, fever, or jaundice",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most effective if used with diuretic; titrate dose to optimal blood pressure control with minimal side effects",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11426618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 50 mg/mL oral suspension may be made with tablets and either unpreserved Simple Syrup, N.F. or a 1:1 mixture of simple syrup (containing 0.5% citric acid) and hydrochloric acid 0.2 N. Crush ten 250 mg tablets in a glass mortar and reduce to a fine powder. To make formulation with unpreserved simple syrup, add small portions of vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     50 mL; transfer to a calibrated bottle; rinse the mortar and pestle several times with vehicle, and add quantity of vehicle sufficient to make 50 mL. To make formulation with the second vehicle, mix powdered tablets with 25 mL of hydrochloric acid 0.2 N (0.73% w/v); dilute this mixture to 50 mL with simple syrup containing 0.5% citric acid by the method described above. Label \"shake well\" and \"protect from light.\" Stable for 14 days when stored in glass prescription bottles in the dark at room temperature or refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Newton DW, Rogers AG, Becker CH, et al, \"Extemporaneous Preparation of Methyldopa in Two Syrup Vehicles,\"",
"     <i>",
"      Am J Hosp Pharm",
"     </i>",
"     , 1975, 32(8):817-21.",
"     <span class=\"pubmed-id\">",
"      238389",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20645/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12597 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_10_20645=[""].join("\n");
var outline_f20_10_20645=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195033\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053943\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053935\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195006\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194989\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053947\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195088\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053946\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195090\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195087\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053952\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053934\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053933\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299698\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194998\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053955\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195001\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195016\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053942\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053932\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053950\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053951\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053940\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053953\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11426618\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12597\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12597|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=related_link\">",
"      Methyldopa: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/6/29797?source=related_link\">",
"      Methyldopa: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_10_20646="Daptomycin: Drug information";
var content_f20_10_20646=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Daptomycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/60/11204?source=see_link\">",
"    see \"Daptomycin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/39/39542?source=see_link\">",
"    see \"Daptomycin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F156919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cubicin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6127324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cubicin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F156936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Cyclic Lipopeptide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F156921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Skin and/or skin structure infections (complicated):",
"     </b>",
"     I.V.: 4 mg/kg once daily for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bacteremia, right-sided native valve endocarditis caused by MSSA or MRSA:",
"     </b>",
"     I.V.: 6 mg/kg once daily for 2-6 weeks (some experts recommend 8-10 mg/kg once daily for complicated bacteremia or infective endocarditis [Liu, 2011])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteomyelitis (unlabeled use):",
"     </b>",
"     I.V.: 6 mg/kg once daily for a minimum of 8 weeks (some experts combine with rifampin) (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prosthetic joint infection (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Enterococcus spp (penicillin-susceptible or -resistant) (alternative treatment):",
"     </i>",
"     6 mg/kg every 24 hours for 4-6 weeks (consider adding an aminoglycoside) followed by an oral antibiotic suppressive regimen (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Staphylococci (oxacillin-sensitive or -resistant) (alternative treatment):",
"     </i>",
"     6 mg/kg every 24 hours for 2-6 weeks used in combination with rifampin followed by oral antibiotic treatment and suppressive regimens (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Septic arthritis (unlabeled use):",
"     </b>",
"     I.V.: 6 mg/kg once daily for 3-4 weeks (Liu, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F156922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F156923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Skin and soft tissue infections: 4 mg/kg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Staphylococcal bacteremia: 6 mg/kg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hemodialysis or peritoneal dialysis (PD):  Dose as in Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute (administer after hemodialysis on dialysis days) or (unlabeled dosing) may administer 6 mg/kg after hemodialysis 3 times weekly (Salama, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     High permeability intermittent hemodialysis removes ~50% during a 4-hour session (Salama, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005):  Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous veno-venous hemodialysis (CVVHD): 8 mg/kg every 48 hours (Vilay, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     For other forms of CRRT (eg, CVVH or CVVHDF), dosing as with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute may result in low C",
"     <sub>",
"      max",
"     </sub>",
"     . May consider 4-6 mg/kg every 24 hours (or 8 mg/kg every 48 hours) depending on site or severity of infection or if not responding to standard dosing; therapeutic drug monitoring and/or more frequent serum CPK levels may be necessary (Heintz, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Slow extended daily dialysis (or extended dialysis): 6 mg/kg every 24 hours (Kielstein, 2010);",
"     <b>",
"      Note:",
"     </b>",
"     Dialysis should be initiated within 8 hours of administering daptomycin dose to avoid dose accumulation.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F1959284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required for mild-to-moderate impairment (Child-Pugh class A or B). Not evaluated in severe hepatic impairment (Child-Pugh class C).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F156900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cubicin&reg;: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F156888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F156904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May administer I.V. push over 2 minutes or infuse IVPB over 30 minutes. Do not use in conjunction with ReadyMED&reg; elastomeric infusion pumps (Cardinal Health, Inc) due to an impurity (2-mercaptobenzothiazole) leaching from the pump system into the daptomycin solution.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F156941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS or LR;",
"     <b>",
"      incompatible",
"     </b>",
"     with dextrose-containing solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aztreonam, caspofungin, ceftazidime, ceftriaxone, dopamine, doripenem, ertapenem, fluconazole, gentamicin, heparin, levofloxacin, lidocaine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F156903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of complicated skin and skin structure infections caused by susceptible aerobic gram-positive organisms;",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     bacteremia, including right-sided native valve infective endocarditis caused by MSSA or MRSA",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F156932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of severe infections caused by MRSA or VRE; treatment of prosthetic joint infection caused by staphylococci (oxacillin-susceptible or -resistant) or",
"     <i>",
"      Enterococcus",
"     </i>",
"     (penicillin-susceptible or -resistant)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3265806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cubicin&reg; may be confused with Cleocin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DAPTOmycin may be confused with DACTINomycin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F156934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (5% to 12%), vomiting (3% to 12%), constipation (6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (2% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (7%), chest pain (7%), hypertension (1% to 6%), hypotension (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (5% to 9%), headache (5% to7%), fever (2% to 7%), dizziness (2% to 6%), anxiety (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (4% to 7%), pruritus (3% to 6%), erythema (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (9%), hyperkalemia (5%), hyperphosphatemia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (6% to 10%), abdominal pain (6%), dyspepsia (1% to 4%), loose stool (4%), GI hemorrhage (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (2% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: INR increased (2%), eosinophilia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (2% to 3%), alkaline phosphatase increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (3% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased (3% to 9%), limb pain (2% to 9%), back pain (7%), weakness (5%), arthralgia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal failure (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngolaryngeal pain (8%), pleural effusion (6%), cough (3%), pneumonia (3%), dyspnea (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Osteomyelitis (6%), bacteremia (5%), diaphoresis (5%), sepsis (5%), infection (fungal, 2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, atrial fibrillation, atrial flutter, candidal infection, cardiac arrest,",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD), coma (post anaesthesia/surgery), eczema, eosinophilic pneumonia, hallucination, hypomagnesemia, hypersensitivity, hypoesthesia, jaundice, LDH increased, lymphadenopathy, mental status change, oral candidiasis, oral hypoesthesia, osteomyelitis, peripheral neuropathy, proteinuria, prothrombin time prolonged, renal impairment, rhabdomyolysis, serum bicarbonate increased, Stevens-Johnson syndrome, stomatitis, supraventricular arrhythmia, thrombocytopenia, thrombocythemia, vaginal candidiasis, vertigo, vesiculobullous rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F156907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to daptomycin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F156890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Eosinophilic pneumonia: Use may result in eosinophilic pneumonia; generally develops 2-4 weeks after therapy initiation. Monitor for signs and symptoms of eosinophilic pneumonia, including new onset or worsening fever, dyspnea, difficulty breathing, new infiltrates on chest imaging studies, and/or &gt;25% eosinophils present in bronchoalveolar lavage. Discontinue use immediately with signs/symptoms of eosinophilic pneumonia and initiate appropriate treatment (ie, corticosteroids). May reoccur with re-exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Hypersensitivity reactions and anaphylaxis have been reported with use; discontinue use immediately with signs/symptoms of hypersensitivity and initiate appropriate treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy: May be associated with an increased incidence of myopathy; discontinue in patients with signs and symptoms of myopathy in conjunction with an increase in CPK (&gt;5 times ULN or 1000 units/L) or in asymptomatic patients with a CPK &ge;10 times ULN. Myopathy may occur more frequently at dose and/or frequency in excess of recommended dosages. Use caution in patients receiving other drugs associated with myopathy (eg, HMG-CoA reductase inhibitors).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: Symptoms suggestive of peripheral neuropathy have been observed with treatment; monitor for new-onset or worsening neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea and pseudomembranous colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute). Limited data (eg, subgroup analysis) from cSSSI and endocarditis trials suggest possibly reduced clinical efficacy (relative to comparators) in patients with baseline moderate renal impairment (&lt;50 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pneumonia use: Not indicated for the treatment of pneumonia due to inactivation by pulmonary surfactant",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F156894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: May enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased. Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F156896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F156909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Successful use of daptomycin during the second and third trimesters of pregnancy has been described; however, only limited information is available from case reports.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F156926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excreted in breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6063936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low concentrations of daptomycin have been detected in breast milk; however, daptomycin is poorly absorbed orally. The manufacturer recommends caution if daptomycin is used during breast-feeding. Per the Canadian product labeling, daptomycin should be discontinued while breast-feeding. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cubicin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $362.51",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F156898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor signs and symptoms of infection. CPK should be monitored at least weekly during therapy; more frequent monitoring if current or prior statin therapy, unexplained CPK increases, and/or renal impairment. Monitor for muscle pain or weakness, especially if noted in distal extremities. Canadian labeling recommends CPK monitoring every 48 hours with unexplained muscle pain, tenderness, weakness or cramps. Monitor for signs/symptoms of eosinophilic pneumonia.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F156901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Trough concentrations at steady-state:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/kg once daily: 5.9 &plusmn; 1.6 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/kg once daily: 6.7 &plusmn; 1.6 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Trough concentrations are not predictive of efficacy/toxicity. Drug exhibits concentration-dependent bactericidal activity, so C",
"     <sub>",
"      max",
"     </sub>",
"     :MIC ratios may be a more useful parameter.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cubicin (AR, AT, AU, BE, BG, CH, CL, CO, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, IE, IL, IT, MT, MY, NL, NO, NZ, PH, PL, PT, RU, SE, SG, SK, TH, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F156889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Daptomycin binds to components of the cell membrane of susceptible organisms and causes rapid depolarization, inhibiting intracellular synthesis of DNA, RNA, and protein. Daptomycin is bactericidal in a concentration-dependent manner.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F156906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : 0.1 L/kg; Critically-ill patients: V",
"     <sub>",
"      ss",
"     </sub>",
"     : 0.23 &plusmn; 0.14 L/kg (Vilay, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90% to 93%; 84% to 88% in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 8-9 hours (up to 28 hours in renal impairment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (78%; primarily as unchanged drug); feces (6%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cha R, Grucz RG Jr, and Rybak MJ, &ldquo;Daptomycin Dose-Effect Relationship Against Resistant Gram-Positive Organisms,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2003, 47(5):1598-603.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/12709328/pubmed\" id=\"12709328\" target=\"_blank\">",
"        12709328",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chakraborty A, Roy S, Loeffler J, et al, &ldquo;Comparison of the Pharmacokinetics, Safety and Tolerability of Daptomycin in Healthy Adult Volunteers Following Intravenous Administration by 30 Min Infusion or 2 Min Injection,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2009, 64(1):151-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/19389714/pubmed\" id=\"19389714\" target=\"_blank\">",
"        19389714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2012, 67(2):269-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/22086858/pubmed\" id=\"22086858\" target=\"_blank\">",
"        22086858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kielstein JT, Eugbers C, Bode-Boeger SM, et al, &ldquo;Dosing of Daptomycin in Intensive Care Unit Patients With Acute Kidney Injury Undergoing Extended Dialysis &ndash; A Pharmacokinetic Study,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2010, 25(5):1537-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/20031929/pubmed\" id=\"20031929\" target=\"_blank\">",
"        20031929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, &ldquo;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus Aureus",
"      </i>",
"      Infections in Adults and Children: Executive Summary,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):285-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/21217178/pubmed\" id=\"21217178\" target=\"_blank\">",
"        21217178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller BA, Gray A, Leblanc TW, et al, &ldquo;Acute Eosinophilic Pneumonia Secondary to Daptomycin: A Report of Three Cases,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 50(11):e63-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/20420515/pubmed\" id=\"20420515\" target=\"_blank\">",
"        20420515",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richter SS, Kealey DE, Murray CT, et al, &ldquo;The",
"      <i>",
"       in vitro",
"      </i>",
"      Activity of Daptomycin Against",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      and",
"      <i>",
"       Enterococcus",
"      </i>",
"      Species,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2003, 52(1):123-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/12805265/pubmed\" id=\"12805265\" target=\"_blank\">",
"        12805265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salama NN, Segal JH, Churchwell MD, et al, &ldquo;Single-Dose Daptomycin Pharmacokinetics in Chronic Haemodialysis Patients,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2010, 25(4):1279-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/20007981/pubmed\" id=\"20007981\" target=\"_blank\">",
"        20007981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverman JA, Mortin LI, Vanpraagh AD, et al, \"Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact,\"",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 2005, 191(12):2149-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/15898002/pubmed\" id=\"15898002\" target=\"_blank\">",
"        15898002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverman JA, Perlmutter NG, and Shapiro HM, &ldquo;Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2003, 47(8):2538-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/12878516/pubmed\" id=\"12878516\" target=\"_blank\">",
"        12878516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tedesco KL and Rybak MJ, &ldquo;Daptomycin,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(1):41-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/14740787/pubmed\" id=\"14740787\" target=\"_blank\">",
"        14740787",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vilay MA, Grio M, DePestel DD, et al, &ldquo;Daptomycin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2011, 39(1):19-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/10/20646/abstract-text/20890189/pubmed\" id=\"20890189\" target=\"_blank\">",
"        20890189",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9304 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_10_20646=[""].join("\n");
var outline_f20_10_20646=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156919\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6127324\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156936\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156921\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156922\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156923\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1959284\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156900\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156888\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156904\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156941\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156903\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156932\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3265806\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156934\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156907\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156890\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299126\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156894\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156896\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156909\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156926\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6063936\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323093\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156898\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156901\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539841\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156889\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156906\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9304\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9304|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/60/11204?source=related_link\">",
"      Daptomycin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/39/39542?source=related_link\">",
"      Daptomycin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_10_20647="Normal variability and accelerations";
var content_f20_10_20647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F86064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F86064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Normal variability and accelerations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce K Young, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_10_20647=[""].join("\n");
var outline_f20_10_20647=null;
var title_f20_10_20648="Diagnosis of latent tuberculosis infection in HIV-negative adults";
var content_f20_10_20648=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of latent tuberculosis infection in HIV-negative adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/10/20648/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/10/20648/contributors\">",
"     Madhukar Pai, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/10/20648/contributors\">",
"     Dick Menzies, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/10/20648/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/10/20648/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/10/20648/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/10/20648/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/10/20648/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While treatment of individuals with active tuberculosis (TB) is the first priority for tuberculosis control, an important second priority is identification and treatment of individuals with latent tuberculosis infection (LTBI).",
"   </p>",
"   <p>",
"    In most individuals, M. tuberculosis infection is contained initially by host defenses, and infection remains latent. However, latent infection has the potential to develop into active disease at any time. Identification and treatment of latent tuberculosis infection can reduce the risk of development of disease by as much as 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/1\">",
"     1",
"    </a>",
"    ], and so has potential to protect the health of the individuals as well as the public by reducing the number of potential sources of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two major tests for identification of latent tuberculosis infection: the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (TST) and the interferon gamma release assay (IGRA). Both tests evaluate cell-mediated immunity.",
"   </p>",
"   <p>",
"    Diagnostic testing for LTBI in HIV-seronegative patients will be reviewed here. Management of LTBI for patients with HIV or receiving tumor necrosis factor-alpha inhibitors is discussed in detail separately, as are issues related to TB screening in children and treatment of latent tuberculosis infection in HIV-seronegative patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13143?source=see_link\">",
"     \"Latent tuberculosis infection in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of testing for latent tuberculosis infection is to identify individuals who are at increased risk for the development of tuberculosis and therefore would benefit from treatment of latent TB infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Only those who would benefit from treatment should be tested, so a decision to test presupposes a decision to treat if the test is positive.",
"   </p>",
"   <p>",
"    In general, testing for latent TB infection is warranted to identify individuals who are at risk of new infection, and to identify individuals at increased risk of reactivation due to associated conditions (",
"    <a class=\"graphic graphic_table graphicRef74584 \" href=\"UTD.htm?35/55/36732\">",
"     table 1",
"    </a>",
"    ). Diagnostic tools for diagnosis of latent TB include tuberculin skin testing (TST) and interferon gamma release assays (IGRAs). The use of the TST for diagnosis of latent TB infection will be reviewed here; the use of IGRAs for diagnosis of latent TB infection is discussed separately. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In general, use of TST or IGRA for the diagnosis of active TB in adults is discouraged. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk of new infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for latent TB should be performed in individuals for whom new infection is suspected. This includes close contacts of patients with active pulmonary TB (eg, those living in the same household), as well as casual contacts of patients with highly contagious active TB (such as healthcare workers). Because the risk of developing active disease is very high in the next few years following exposure, all patients at increased risk for new TB infection should be evaluated for LTBI, regardless of age (",
"    <a class=\"graphic graphic_table graphicRef74584 \" href=\"UTD.htm?35/55/36732\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In general, close contacts of patients with active pulmonary TB should undergo a second test 8 to 12 weeks later if the first test is negative. Healthcare workers should undergo baseline two step testing followed by annual testing (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Repeat and serial testing'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The risk of disease in the first two years following infection is age dependent. The decline of risk with increasing age reflects greater innate and acquired immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infants (ages &le;1): 50 percent",
"     </li>",
"     <li>",
"      Children (ages 1 to 2): 12 to 25 percent",
"     </li>",
"     <li>",
"      Children (ages 2 to 5): 5 percent",
"     </li>",
"     <li>",
"      Children (ages 5 to 10): 2 percent",
"     </li>",
"     <li>",
"      Age &gt;10 years: 10 to 20 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Increased risk of reactivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying those at risk for reactivation who warrant testing depends on age and the degree of risk for reactivation (relative to healthy individuals) (",
"    <a class=\"graphic graphic_table graphicRef74584 \" href=\"UTD.htm?35/55/36732\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60941 \" href=\"UTD.htm?38/36/39502\">",
"     table 2",
"    </a>",
"    ). In general, individuals at increased risk of reactivation require a single test only; if it is negative, no further testing is needed.",
"   </p>",
"   <p>",
"    Normal healthy individuals with LTBI have an annual risk of 0.1 percent (1 per 1000) of developing active TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/7\">",
"     7",
"    </a>",
"    ]. Annual risk of disease if infected can range from more than 10 percent (with HIV infection) to 1 to 2 percent (if on hemodialysis or following solid organ transplant) to 0.1 percent (if healthy with a normal chest x-ray). Estimated risks for TB relative to healthy individuals in the setting of various conditions are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef60941 \" href=\"UTD.htm?38/36/39502\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High risk &mdash; High risk individuals are those whose risk for reactivation is at least six times higher than normal healthy individuals. These include individuals with major immunocompromising conditions (eg, lymphoma, leukemia, head and neck cancer, chemotherapy, solid organ transplant, HIV infection, TNF-alpha inhibitors), and those with chest x-ray demonstrating fibronodular changes typical of healed TB (so called \"inactive TB\"). All individuals in these categories should have a single test to evaluate for latent TB infection, regardless of age.",
"     </li>",
"     <li>",
"      Moderate risk &mdash; Moderate risk individuals are those whose risk for reactivation is three to six times higher than normal healthy individuals. These include individuals with diabetes mellitus (regardless of insulin dependence) or corticosteroid therapy. All individuals in these categories &le;65 should have a single test to evaluate for latent TB infection.",
"     </li>",
"     <li>",
"      Slightly increased risk &mdash; Individuals at slightly increased risk for reactivation are those whose risk is 1.5 to 3 times higher than normal healthy individuals. This includes individuals who are underweight, smoke cigarettes, or have small granulomas on chest X-ray. All individuals &le;50 in this category should have a single test to evaluate for latent TB infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of isoniazid-induced hepatitis and other adverse events increases with age; risk of hepatitis increases over the age of 35, and substantially over the age of 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Therefore, age is an important consideration in the decision to test for LTBI, since testing implies that treatment will be administered if the test is positive [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Although the annual risk of disease is relatively high, with increasing age the cumulative risk of reactivation diminishes, as does the benefit of therapy. To estimate the cumulative lifetime risk with various conditions, a web-based algorithm can be used [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We favor the following age parameters for LTBI testing (with intention to treat if test is positive) (",
"    <a class=\"graphic graphic_table graphicRef74584 \" href=\"UTD.htm?35/55/36732\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For individuals &ge;65, the risk of hepatitis is &ge;5 percent, so testing and treatment are indicated only if risk of reactivation is high [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For individuals between 50 and 65, the risk of hepatitis is 3 to 5 percent, which is sufficiently high that testing and treatment are indicated if risk of reactivation is high or moderate.",
"     </li>",
"     <li>",
"      For individuals &lt;50, risk of hepatitis is less than 3 percent (for individuals &lt;35 it is less than 1 percent), so testing and treatment are indicated if risk of reactivation is slightly increased, moderate, or high.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Testing and treatment are not warranted for individuals &ge;50 with only slightly increased risk and individuals &ge;65 with moderate or slightly increased risk for reactivation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TUBERCULIN SKIN TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    (TST) is used to identify individuals with previous sensitization to mycobacterial antigens. It consists of intradermal injection of tuberculin material, which stimulates a delayed type hypersensitivity response mediated by T lymphocytes and causes induration within 48 to 72 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Performing the TST",
"    </span>",
"    &nbsp;&mdash;&nbsp;In North America, the tuberculin material is purified protein derivative (PPD); the recommend dose is 5 tuberculin units (0.1 mL). In other regions, RT-23 may be the tuberculin material used; the standard dose is 2 tuberculin units. These doses have been shown to be equivalent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only recommended method of tuberculin skin testing is the Mantoux technique, which consists of intradermal injection of tuberculin material on the inner surface of the forearm [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. To read the test, the transverse diameter of the induration (not erythema) should be demarcated, measured, and recorded in millimeters. The test should be read 48 to 72 hours following intradermal injection.",
"   </p>",
"   <p>",
"    The results are less reliable if the test is read after 72 hours. Among 400 individuals with positive TST at 48 to 72 hours, about 20 percent had negative results when the TST was read seven days after placement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/14\">",
"     14",
"    </a>",
"    ]. While a strongly positive reaction after 96 hours may be accepted, results become increasingly doubtful with longer intervals between injection and reading; in such circumstances, it is best is to repeat the TST. If the TST is repeated after seven days, then the boosting effect may cause a positive TST (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Booster response'",
"    </a>",
"    below). However, in the absence of a documented negative first TST, there is no way to know if the TST represents a boosted reaction. Hence, the TST must be interpreted in the same way as a single initial TST. This potential problem reinforces the importance of reading at the correct time.",
"   </p>",
"   <p>",
"    Multipuncture methods (including the Tine test and the Heaf test) may be easier to administer, but are not accurate because it is not possible to precisely control the amount of tuberculin. Therefore, these should not be used [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Repeat and serial testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the TST is documented to be positive, it should never be repeated. Once the test is positive, it will remain positive, and repeating the test has no clinical utility. If there is a history of a positive TST but this is not documented, then it may be appropriate to confirm this.",
"   </p>",
"   <p>",
"    If the TST is negative, there are three circumstances in which the TST should be repeated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Close contacts of patients with active pulmonary TB &mdash; These individuals may have an initial negative TST because the TB infection was so recent that delayed hypersensitivity has not yet developed. In these individuals, the TST should be repeated eight weeks after the last exposure, since it takes three to seven weeks for tuberculin conversion to occur after new infection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/15\">",
"       15",
"      </a>",
"      ]. The same technique and dosage is used, but the test is applied on the opposite forearm.",
"     </li>",
"     <li>",
"      Individuals with ongoing potential exposure &mdash; In North America, ongoing potential exposure occurs in the setting of occupational risk; healthcare workers in institutions with a substantial risk of unrecognized exposure to tuberculosis represent the major group for which serial annual testing is warranted. Those undergoing serial annual testing should also receive additional testing after a known episode of exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/16\">",
"       16",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Individuals with ongoing potential exposure who have a history of a positive test for latent TB infection and have completed a course of LTBI treatment should undergo baseline chest x-ray. Reevaluation with chest x-ray should be pursued if symptoms develop that raise the possibility of active tuberculosis. There are no additional mechanisms to evaluate for subsequent TB exposure in these individuals.",
"      <br/>",
"      <br/>",
"      Serial testing is NOT warranted for groups other than those with occupational risk (such as those with increased risk of reactivation) in settings where the incidence of TB is very low (less than 1 per 1000 per year). In areas where TB incidence and the annual risk of infection are high, routine serial testing is usually not performed because of limited resources in these settings [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      To establish a correct baseline prior to serial testing (\"two step testing\") &mdash; In individuals with remote exposure to mycobacterial antigens (eg, due to prior BCG vaccination, nontuberculous mycobacteria exposure, or remote TB infection), the tuberculin reaction may have waned and an initial tuberculin test may be negative [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. However, placement of the initial tuberculin test stimulates anamnestic recall of immunity, such that a second tuberculin test (\"booster\") will be positive. Therefore, in the setting of a positive tuberculin test performed a year after initial screening, it may be difficult to distinguish between recent infection and remote mycobacterial exposure. For this reason, evaluation for the \"booster phenomenon\" should be performed by repeating the TST (on the opposite forearm) one to four weeks after the first test. The induration observed with the second test is the baseline that should be used for subsequent evaluation of skin test conversion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interpretation of repeat and serial skin testing is discussed below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Repeat TST interpretation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INTERPRETING THE TST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TST reading must establish a positive or negative result in order to determine subsequent management (",
"    <a class=\"graphic graphic_table graphicRef67357 \" href=\"UTD.htm?31/0/31756\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Sensitivity is 98 percent using the 5 mm threshold, 90 percent using the 10 mm threshold, but only 50 to 60 percent using the 15 mm threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/21\">",
"     21",
"    </a>",
"    ]. As the cutoff for mm of induration is increased, the sensitivity decreases and the specificity increases. A higher cut-off is useful for evaluation of individuals in regions with high prevalence of nontuberculous mycobacterial exposure and low likelihood of true TB infection.",
"   </p>",
"   <p>",
"    If the TST is negative, the possibility of a false negative result must be considered, as discussed in the following section. Repeat testing is warranted in the circumstances outlined above. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Repeat and serial testing'",
"    </a>",
"    above.).",
"   </p>",
"   <p>",
"    If the test is positive, no further testing is warranted. The patient should be referred for medical evaluation to exclude active TB, followed by initiation of treatment for latent TB infection. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Positive tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Negative tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     False negative tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;False negative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    results may occur in the setting of biological and technical limitations (",
"    <a class=\"graphic graphic_table graphicRef58908 \" href=\"UTD.htm?8/46/8940\">",
"     table 4",
"    </a>",
"    ). Biologic limitations include immunosuppression or natural waning of immunity. Technical limitations include improper tuberculin handling and interpretation.",
"   </p>",
"   <p>",
"    Anergy testing with control antigens such as mumps and Candida was previously thought to help determine between true negative and false negative tuberculin tests. However, the role of anergy testing in the diagnosis of LTBI is not well defined, and not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/10,13\">",
"     10,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Treating negative tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of recent close contact to individuals known to have infectious tuberculosis, treatment for LTBI should be considered for adults who are severely immunocompromised (such as HIV infected or organ transplant recipient)&mdash;even with negative TST or IGRA.",
"   </p>",
"   <p>",
"    For these patients, LTBI therapy should be initiated (following clinical evaluation to rule out active tuberculosis) and the TST or IGRA repeated after eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/15\">",
"     15",
"    </a>",
"    ]. If the second test is positive, treatment should be continued; if the test is negative, treatment is usually stopped, although continued therapy may be considered on an individual basis.",
"   </p>",
"   <p>",
"    The approach to treatment is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Positive tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The positive predictive value (PPV) denotes the probability of true infection in the setting of a positive test. The greater the risk of exposure (due to risk factors such as close contacts with active TB cases and foreign born status), the higher the PPV. A computer based algorithm is available to assist in the interpretation of TST [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     False positive tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two important causes of false positive tests: nontuberculous mycobacteria infection and BCG vaccination. However, in individuals with high likelihood of LTBI",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high risk of development of disease if infected, potential causes of false positive tests should not influence the decision to administer LTBI therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nontuberculous mycobacteria &mdash; Infection with nontuberculous mycobacteria (NTM) may cause false positive reactions to tuberculin. Estimates of the frequency of false positive TSTs due to NTM range from 1 to 5 percent of positive tuberculin tests [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/22\">",
"       22",
"      </a>",
"      ] to as many as 50 percent of 9 to 14 mm reactions in US healthcare workers [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/11\">",
"       11",
"      </a>",
"      ]. Therefore, the effect is important only if prevalence of true TB infection is low (ie, less than 5 percent). This situation occurs in low incidence countries with tropical, sub-tropical or temperate climates [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/11,22\">",
"       11,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      BCG vaccination &mdash; BCG vaccination is a well known but frequently misunderstood cause of false positive tuberculin reactions. The effect of BCG on TST depends primarily on the age when vaccinated [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/22\">",
"       22",
"      </a>",
"      ]. BCG vaccination in the first year of life causes no discernable effect on TST after 10 years or more. Vaccination after the first year of life (such as at entrance to primary school at the age 5 to 6) causes a stronger and longer lasting effect. As many as 20 percent of individuals remain positive 10 years or more after vaccination at this age. In pediatric populations, the interval since vaccination is important since there is progressive waning over the first 10 years after vaccination.",
"      <br/>",
"      <br/>",
"      Since many foreign-born persons do not know their BCG vaccination status or age at vaccination, current and past BCG vaccination policies for most countries of the world may be reviewed online at the World Atlas of BCG Policies and Practices [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/23\">",
"       23",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      TST reactivity caused by BCG sensitization can be distinguished from latent TB infection by interferon-gamma release assays. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link\">",
"       \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Treating positive tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with positive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    or IGRA results must undergo clinical evaluation to rule out active tuberculosis prior to treatment for latent infection. This includes evaluation for symptoms (eg, fever, cough, weight loss), physical examination, and radiographic examination of the chest.",
"   </p>",
"   <p>",
"    A chest radiograph is considered abnormal if it demonstrates parenchymal abnormalities, particularly upper lobe opacification. Radiographs demonstrating stable upper lobe fibro-nodular disease or calcified granulomas are considered to have evidence of previous tuberculosis, and indicate the patient is at increased risk of reactivation (",
"    <a class=\"graphic graphic_table graphicRef60941 \" href=\"UTD.htm?38/36/39502\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with symptoms or radiographic signs suggestive of active disease should undergo evaluation with sputum microscopy and culture and receive treatment as appropriate. Sputum induction should be performed if patients cannot expectorate spontaneously. Symptoms related to extrapulmonary sites should also be evaluated as appropriate. In addition, HIV testing should be considered in patients with LTBI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The approach to treatment is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Healthcare workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthcare workers should undergo baseline two step testing followed by annual testing. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Repeat and serial testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The clinical approach for healthcare worker exposure to active contagious TB varies depending on TST status and the interval since the exposure episode. In general, if primary TB infection develops following clinical exposure, TST conversion occurs three to eight weeks later. Therefore, for TST to reflect recent TB infection it must be performed &ge;3 weeks following exposure. The clinical approach is outlined below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For individuals with prior negative tuberculin test (ideally a negative two-step TST) and low likelihood of interim exposure, a single tuberculin test should be performed eight weeks following exposure. If positive at &ge;5 mm, this should be interpreted as a recent TST conversion.",
"     </li>",
"     <li>",
"      For individuals without prior tuberculin testing born in a low TB-incidence country and no history of BCG vaccination, a baseline tuberculin test could be performed immediately (ie, &le;2.5 weeks or about 18 days following exposure). If positive, this is suggestive of prior LTBI infection. If negative, a second TST can be performed eight weeks after the end of exposure. If positive at &ge;5 mm, this should be managed as a recent TST conversion.",
"     </li>",
"     <li>",
"      For individuals without prior tuberculin testing born in a medium to high TB incidence country",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      who have history of BCG vaccination, baseline two step tuberculin testing could be performed promptly so long as both first and second steps can be completed within &le;2.5 weeks (ie, about 18 days) from the start of exposure. If positive at &ge;5 mm, this is suggestive of prior LTBI infection. If negative, a second TST can be performed eight weeks after the end of exposure. If the second TST is positive, this should be managed as a recent TST conversion. IGRA is not an appropriate diagnostic tool for such circumstances, as the interval between primary TB infection and IGRA conversion is not fully understood, and there is no consensus on how to interpret IGRA conversions and reversions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link\">",
"       \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early reaction within 24 hours with absence of induration at 48 to 72 hours is considered an allergic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/24\">",
"     24",
"    </a>",
"    ]. Immediate hypersensitivity skin reactions to the TST are possible; these consist of wheal and flare response at the testing site within 20 minutes of PPD placement. In a case series of 3248 allergy clinic patients, immediate hypersensitivity to skin testing with PPD was observed in 2 to 3 percent of patients, without systemic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/24\">",
"     24",
"    </a>",
"    ]. Systemic allergic reactions (including urticaria, angioedema, dyspnea, and anaphylaxis) are rarely reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The incidence is estimated to be 1 to 3 per million distributed doses, which is similar to the rate of anaphylaxis with vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link\">",
"     \"Allergic reactions to vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our experience, a diffuse maculopapular rash can appear within 12 hours and resolve within in a day or two, although such allergic reactions to the TST are relatively uncommon. The incidence of these reactions in our clinic is in the range of one reaction per 2000 to 3000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/27\">",
"     27",
"    </a>",
"    ]. These allergic reactions are unrelated to the TST result at 48 to 72 hours.",
"   </p>",
"   <p>",
"    Patients with immediate skin test reactions or other types of allergic reactions to the TST should not receive it again. The best approach for individuals who require serial testing has not been studied. Our practice is to assess patients annually for symptoms of active disease, and obtain a chest radiograph if new symptoms develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Managing referrals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may be referred after a TST is performed for expert guidance regarding initiation of LTBI therapy. In such cases it is imperative to review the indications for skin testing as outlined in the preceding sections. LTBI treatment should be initiated only for patients in the categories for which treatment confers benefit. Those who have undergone testing who fall outside these categories should not receive LTBI therapy, as risk outweighs potential benefit. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Indications for testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     REPEAT TST INTERPRETATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interpretation of serial or repeated TST depends on the context [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Repeat and serial testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Booster response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Booster response refers to a positive TST performed one to four weeks after an initial negative TST in the absence of exposure (such as pre-employment screening of healthcare workers). The booster response is less specific for diagnosis of LTBI than the initial TST since the booster response may be caused by prior BCG vaccination, sensitization to nontuberculous mycobacteria, or remote TB infection. Therefore, the risk of developing active TB among individuals with a booster response is lower than the risk of developing active TB among individuals with an initial positive TST [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/8,28\">",
"     8,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Conversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin test conversion refers to one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive TST up to eight weeks after an initial negative TST in the setting of recent exposure. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk of new infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A positive TST detected as part of serial testing with ongoing risk of exposure (such as healthcare workers), in the setting of baseline negative TST.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of developing active TB is much higher in the setting of skin test conversion than booster response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;For both boosting and conversion, the second TST is defined as positive if the induration measures 10 mm or greater and has increased by &ge;6 mm since the previous test [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20648/abstract/15\">",
"     15",
"    </a>",
"    ]. This definition is used because test variability may cause increases in induration of up to 6 mm.",
"   </p>",
"   <p>",
"    Criteria for boosting and conversion of 12 mm, 15 mm, or even 18 mm have been suggested; these may be more specific but are much less sensitive. Individuals with reactions of &ge;10 mm should be referred for medical evaluation to exclude active TB prior to initiation of LTBI therapy. The reaction should be documented, and no further tuberculin testing should be done.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     INTERFERON GAMMA RELEASE ASSAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to interferon-gamma release assays (IGRAs) and their use are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=see_link\">",
"       \"Patient information: Tuberculosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification and treatment of latent tuberculosis infection (LTBI) can greatly reduce the likelihood of reactivation. Hence this has the potential to protect both individual and public health by reducing the number of potential sources of infection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testing for and treatment of LTBI should be pursued in patients at increased risk for tuberculosis because of certain clinical conditions,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in patients with recent close contact to persons known to have infectious tuberculosis (",
"      <a class=\"graphic graphic_table graphicRef74584 \" href=\"UTD.htm?35/55/36732\">",
"       table 1",
"      </a>",
"      ). LTBI testing is appropriate only for those who would benefit from treatment; a decision to test implies a decision to treat if the test is positive. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since isoniazid-induced hepatitis increases with age, we suggest the following age parameters for LTBI testing (with intention to treat if test is positive) (",
"      <a class=\"graphic graphic_table graphicRef74584 \" href=\"UTD.htm?35/55/36732\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef60941 \" href=\"UTD.htm?38/36/39502\">",
"       table 2",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For individuals &ge;65, testing is indicated if risk of reactivation is high",
"     </li>",
"     <li>",
"      For individuals between 50 and 65, testing is indicated if risk of reactivation is moderate or high.",
"     </li>",
"     <li>",
"      For individuals &lt;50, testing is indicated if risk of reactivation is slightly increased, moderate or high. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Age'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      assesses the intradermal delayed type hypersensitivity response produced by administration of purified protein derivative (PPD) from M. tuberculosis. The interpretation is outlined in the Table (",
"      <a class=\"graphic graphic_table graphicRef67357 \" href=\"UTD.htm?31/0/31756\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Tuberculin skin test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A period of up to eight weeks after primary TB infection may be required for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      conversion to occur. Individuals with recent close contact to a known infectious case of tuberculosis, whose initial TST is negative, should have repeat TST eight weeks after the end of exposure. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Repeat and serial testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TST can be false negative because of because of biologic problems (such as immune suppression), or because of technical problems with the TST administration, PPD material, or reading (",
"      <a class=\"graphic graphic_table graphicRef58908 \" href=\"UTD.htm?8/46/8940\">",
"       table 4",
"      </a>",
"      ). TST can be false positive because of nontuberculous mycobacteria or BCG vaccination. However, in individuals with high likelihood of LTBI",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      high risk of development of disease if infected, potential causes of false positive tests should not influence the decision to administer LTBI therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Interpreting the TST'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For severely immunocompromised persons who have had recent close contact with known infectious cases of tuberculosis, LTBI therapy may be started even if initial TST is negative. These tests for LTBI should be repeated after eight weeks. If the second test is now positive, treatment is continued. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treating negative tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with positive TST or IGRA results must undergo clinical evaluation to rule out active tuberculosis and to assess need for LTBI therapy. This includes evaluation for symptoms (eg, fever, cough, weight loss), physical exam, and radiographic examination of the chest. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treating positive tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tuberculin boosting is defined as an increase to an induration of at least 10 mm, compared with a TST that was previously negative (&lt;10 mm) in the absence of any exposure (and usually within one to four weeks). Tuberculin conversion is defined as an increase in induration of at least 10 mm, compared with a TST that was previously negative (&lt;10 mm) in the setting of potential exposure. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Repeat TST interpretation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/1\">",
"      Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/2\">",
"      Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350:2060.",
"     </a>",
"    </li>",
"    <li>",
"     Rieder HL. Interventions for Tuberculosis Control and Elimination. International Union Against Tuberculosis and Lung Disease, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/4\">",
"      Horsburgh CR Jr, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med 2011; 364:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/5\">",
"      Mancuso JD, Tribble D, Mazurek GH, et al. Impact of targeted testing for latent tuberculosis infection using commercially available diagnostics. Clin Infect Dis 2011; 53:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/6\">",
"      Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004; 8:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/7\">",
"      Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the U.S. Navy: its distribution and decline. Am Rev Respir Dis 1974; 110:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/8\">",
"      Stead WW, To T, Harrison RW, Abraham JH 3rd. Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med 1987; 107:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/9\">",
"      Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/10\">",
"      Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161:S221.",
"     </a>",
"    </li>",
"    <li>",
"     The Online TST/QFT Interpreter. Version 2.0. file://www.tstin3d.com/index.html (Accessed on September 24, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/12\">",
"      COMSTOCK GW, EDWARDS LB, PHILIP RN, WINN WA. A COMPARISON IN THE UNITED STATES OF AMERICA OF TWO TUBERCULINS, PPD-S AND RT 23. Bull World Health Organ 1964; 31:161.",
"     </a>",
"    </li>",
"    <li>",
"     Menzies D, Doherty TM. Diagnosis of latent tuberculosis infection. In: Reichman and Hershfield's Tuberculosis, a comprehensive international approach, Raviglione MC (Ed), Informa Healthcare USA, New York 2006. p.215.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/14\">",
"      DUBOCZY BO, BROWN BT. Multiple readings and determination of maximal intensity of tuberculin reaction. Am Rev Respir Dis 1961; 84:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/15\">",
"      Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999; 159:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/16\">",
"      Jensen PA, Lambert LA, Iademarco MF, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings. WHO/CDS/TB/99.269. IJTLD 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/18\">",
"      Menzies R, Vissandjee B, Rocher I, St Germain Y. The booster effect in two-step tuberculin testing among young adults in Montreal. Ann Intern Med 1994; 120:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/19\">",
"      Richards NM, Nelson KE, Batt MD, et al. Tuberculin test conversion during repeated skin testing, associated with sensitivity to nontuberculous mycobacteria. Am Rev Respir Dis 1979; 120:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/20\">",
"      Gordin FM, Perez-Stable EJ, Flaherty D, et al. Evaluation of a third sequential tuberculin skin test in a chronic care population. Am Rev Respir Dis 1988; 137:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/21\">",
"      FURTHER studies of geographic variation in naturally acquired tuberculin sensitivity. Bull World Health Organ 1955; 12:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/22\">",
"      Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10:1192.",
"     </a>",
"    </li>",
"    <li>",
"     A World Atlas of BCG Vaccination Policies and Practices file://www.bcgatlas.org/ (Accessed on April 01, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/24\">",
"      Tarlo SM, Day JH, Mann P, Day MP. Immediate hypersensitivity to tuberculin. In vivo and in vitro studies. Chest 1977; 71:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/25\">",
"      Youssef E, Wooltorton E. Serious allergic reactions following tuberculin skin tests. CMAJ 2005; 173:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/26\">",
"      Froeschle JE, Ruben FL, Bloh AM. Immediate hypersensitivity reactions after use of tuberculin skin testing. Clin Infect Dis 2002; 34:E12.",
"     </a>",
"    </li>",
"    <li>",
"     Richard Menzies, MD, MSc, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20648/abstract/28\">",
"      Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. Adv Tuberc Res 1969; 17:28.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8005 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_10_20648=[""].join("\n");
var outline_f20_10_20648=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk of new infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Increased risk of reactivation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TUBERCULIN SKIN TEST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Performing the TST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Repeat and serial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INTERPRETING THE TST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Negative tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - False negative tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Treating negative tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Positive tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - False positive tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Treating positive tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Healthcare workers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Managing referrals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      REPEAT TST INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Booster response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Conversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      INTERFERON GAMMA RELEASE ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8005\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8005|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/55/36732\" title=\"table 1\">",
"      Who should be tested LTBI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/36/39502\" title=\"table 2\">",
"      Active TB risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/0/31756\" title=\"table 3\">",
"      Tuberculin skin test interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/46/8940\" title=\"table 4\">",
"      Causes of false negative TST",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13143?source=related_link\">",
"      Latent tuberculosis infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=related_link\">",
"      Patient information: Tuberculosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4298?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_10_20649="Breast development and morphology";
var content_f20_10_20649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Breast development and morphology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/10/20649/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/10/20649/contributors\">",
"     Jose Russo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/10/20649/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/10/20649/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/10/20649/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/10/20649/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/10/20649/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The breast undergoes dramatic changes in size, shape, and function in association with puberty, pregnancy, and lactation. It is also the origin of the most common malignancy in women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/1\">",
"     1",
"    </a>",
"    ]. The risk of developing breast cancer has been linked to both endogenous (eg, nulliparity, early menarche, older age at first pregnancy) and exogenous hormonal influences [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The molecular mechanisms underlying the development of breast cancer, particularly estrogen-associated breast carcinogenesis, are incompletely understood. Increasing evidence points to developmental differences in the breast that may influence the risk of developing cancer. Thus, an understanding of breast development and morphology, and the biochemical factors that influence them, is pertinent to the study of both premalignant and malignant conditions affecting the breast.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mature adult breast lies between the second and sixth ribs in the vertical axis, and between the sternal edge and the midaxillary line in the horizontal axis. Breast tissue also projects into the axilla as the axillary tail of Spence. The breast comprises three major structures: skin, subcutaneous tissue, and breast tissue, which is composed of both epithelial and stromal elements. The epithelial components are branching ducts which connect the structural and functional units of the breast (the lobules) to the nipple. The stroma, which comprises the majority of the breast volume in the non-lactating state, is composed of adipose and fibrous connective tissue (",
"    <a class=\"graphic graphic_picture graphicRef68667 \" href=\"UTD.htm?16/47/17145\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The skin of the breast is thin, and contains hair follicles, sebaceous glands, and exocrine sweat glands. The nipple has abundant sensory nerve endings, sebaceous and apocrine sweat glands, but not hair follicles. The areola is circular and pigmented, measuring 15 to 60 mm in diameter. The Morgagni tubercles, which are located near the periphery of the areola, are elevations formed by the openings of the ducts of the Montgomery glands, large sebaceous glands that represent an intermediate stage between sweat and mammary glands.",
"   </p>",
"   <p>",
"    The superficial pectoral fascia envelops the breast, and is continuous with the superficial abdominal fascia (of Camper). The undersurface of the breast lies on the deep pectoral fascia, covering the pectoralis major and serratus anterior muscles. Connecting these two fascial layers are fibrous bands (the Cooper suspensory ligaments) that represent a natural means of support for the breast.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Blood supply and lymphatic drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal blood supply of the breast is derived from the internal mammary artery. Approximately one-third of the blood supply (mainly to the upper outer quadrant) is provided by the lateral thoracic arteries.",
"   </p>",
"   <p>",
"    The lymphatic drainage of the breast is through both superficial (subepithelial and subdermal) and deep lymphatic vessels, and the lymph flows unidirectionally from the superficial to the deep plexus. Lymph flow from the deep subcutaneous and intramammary vessels moves centrifugally toward the axillary and internal mammary (IM) lymph nodes. Approximately 3 percent of the lymph from the breast is estimated to flow to the IM chain, whereas 97 percent flows to the axillary nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Largely for the purpose of determining metastatic progression in breast cancer, axillary lymph nodes are grouped by anatomic location, and often described by dividing them into arbitrary levels. Level I lymph nodes lie lateral to the lateral border of the pectoralis minor muscle, level II nodes lie behind the pectoralis minor muscle, and level III nodes are located medial to the medial border of the pectoralis minor muscle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link&amp;anchor=H10450984#H10450984\">",
"     \"Management of the regional lymph nodes in breast cancer\", section on 'Extent of dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The IM lymph nodes lie within extrapleural fat in the intercostal spaces in close proximity to the IM vessels. Like the axillary nodes, the IM nodes receive lymph drainage from all quadrants of the breast [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/7\">",
"     7",
"    </a>",
"    ]. The number of lymph nodes described in the IM chain is variable. Nodes can extend from the fifth intercostal space to the retroclavicular region, but the most prevalent ones are in the upper three interspaces (",
"    <a class=\"graphic graphic_figure graphicRef74746 \" href=\"UTD.htm?8/34/8744\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NORMAL DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human breast development is a progressive process that is initiated during embryonic life. Although puberty marks the beginning of glandular maturation, full breast differentiation is attained only with subsequent pregnancy and lactation.",
"   </p>",
"   <p>",
"    At birth, the breast rudiment is formed by 10 to 12 primitive ductal elements located beneath the nipple-areola complex. In the prepubertal years, these ducts exhibit relatively slow but steady growth and branching, with canalization into ductal structures. In boys, breast development ceases at this stage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pubertal changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In girls, puberty usually begins around age 10 to 12 under the influence of hypothalamic gonadotropin-releasing hormone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=see_link\">",
"     \"Physiology of gonadotropin-releasing hormone\"",
"    </a>",
"    .) The cells of the anterior pituitary gland release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which promote maturation of the ovarian follicles, and their secretion of estrogens, primarily in the form of 17-beta estradiol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41672?source=see_link\">",
"     \"Molecular biology and physiology of estrogen action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Breast development from puberty to adulthood can be defined by several parameters, including external appearance, volume, number of structures present in the mammary gland, and the degree of branching or differentiation of the individual structures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/3\">",
"     3",
"    </a>",
"    ]. The external appearance of the breast from childhood to maturity has been divided into five phases by Tanner (",
"    <a class=\"graphic graphic_picture graphicRef72038 \" href=\"UTD.htm?10/43/10932\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lobule formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;From a microanatomic standpoint, puberty is marked by increased growth and branching of the ducts to form club-shaped terminal end buds; this is accompanied by an increase in the stromal component [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/3\">",
"     3",
"    </a>",
"    ]. Growing terminal end buds form new branches, twigs, and small ductules (termed alveolar buds). We use the term alveolar bud to identify those structures that are morphologically more developed than the terminal end bud, but more primitive than the terminal structure of the mature resting breast, the acinus. With further branching, alveolar buds become smaller and more numerous, and then they are called ductules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Type 1 lobules",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an average of 11 alveolar",
"    <span class=\"nowrap\">",
"     buds/ductules",
"    </span>",
"    cluster around a terminal duct, they form the type 1 (virginal) lobule (",
"    <a class=\"graphic graphic_picture graphicRef52636 \" href=\"UTD.htm?37/39/38517\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Lobule formation is apparent within one to two years after the onset of the menses. Thereafter, glandular development is variable. Full differentiation of the mammary gland to its maximal degree of branching and secretory activity is a gradual process that takes many years; it may never be attained if pregnancy does not supervene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Type 2 and 3 lobules",
"    </span>",
"    &nbsp;&mdash;&nbsp;The breast tissue of adult women contains two other identifiable types of lobules in addition to the type 1 lobule. The changing levels of estrogen and progesterone during menstrual cycles stimulate the type 1 lobule to sprout new alveolar buds and gradually evolve to more mature structures called type 2 and type 3 lobules (",
"    <a class=\"graphic graphic_picture graphicRef64382 \" href=\"UTD.htm?8/54/9060\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72142 \" href=\"UTD.htm?13/24/13699\">",
"     picture 5",
"    </a>",
"    ). The number of alveolar buds per lobule increases from approximately 11 in the type 1 lobule, to 47 in type 2 lobule and 80 in type 3 lobule, respectively (",
"    <a class=\"graphic graphic_table graphicRef74484 \" href=\"UTD.htm?13/47/14075\">",
"     table 1",
"    </a>",
"    ). This increases the size of the lobules, and reduces the size of each individual alveolar bud. The alveolar buds composing a type 1 lobule are practically twice the size of those of type 2 lobules, whereas the reduction in size in ductules (or alveoli) of type 3 lobules is less dramatic, although still significant (",
"    <a class=\"graphic graphic_table graphicRef74484 \" href=\"UTD.htm?13/47/14075\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Parity and age both influence breast architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. The breasts of nulliparous women contain more undifferentiated structures, such as terminal ducts and type 1 lobules (65 to 80 percent of the total lobular component), with only occasional type 2 and 3 lobules. All of these structures are found in an almost constant proportion through the woman's life span, and are not influenced by age or menopausal status. In contrast, the predominant structure in the breast of parous premenopausal women is the most differentiated type 3 lobule (70 to 90 percent of all lobules). In such women, the frequency of type 3 lobules peaks during the early reproductive years, and starts to decrease in the 30s, probably due to their involution (regression) to predominantly type 1 lobules. By the end of the 40s, the breasts of both nulliparous and parous women are architecturally similar, containing predominantly type 1 lobules. However, they differ markedly with regard to cell kinetics and biologic behavior. In parous women, a first full-term pregnancy between the ages of 14 and 20 correlates with a significant increase in the number of type 3 lobules that predominate until the age of 40, after which a decrease in the number of type 3 lobules occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/3\">",
"     3",
"    </a>",
"    ]. This fact may provide some explanation as to the protective effects of an early first pregnancy on the risk of breast cancer (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Menopause'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Type 4 lobules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progression from type 3 to type 4 lobules is attained during pregnancy (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Early pregnancy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pregnancy and lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pregnant woman undergoes anatomic and physiologic changes in almost every organ system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13274?source=see_link\">",
"     \"Maternal endocrine and metabolic adaptation to pregnancy\"",
"    </a>",
"    .) During this time, the maximum branching capability of the breast is expressed, and the secretory acinus that is formed during pregnancy represents a terminal outgrowth that marks the full extent of glandular differentiation. Fully differentiated secretory cells are characterized by their ability to synthesize and secrete milk proteins (caseins) and lipids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6519?source=see_link\">",
"     \"Physiology of lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During pregnancy, the breast attains its maximum development in two distinct phases, characteristic of the early and late stages of pregnancy. Ductular sprouting predominates in the first trimester, while lobular formation exceeds ductal sprouting in the second trimester.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Early pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under the influence of chorionic gonadotropin, many secretory glands develop from each bud, forming the type 3 lobule. Further proliferation of the distal elements of the ductal tree marks the progression from type 3 lobule to a type 4 lobule (",
"    <a class=\"graphic graphic_picture graphicRef51142 \" href=\"UTD.htm?22/40/23174\">",
"     picture 6",
"    </a>",
"    ). In these newly formed lobules, the epithelial cells composing each acinus not only increase greatly in number due to active cell division but they also increase in size mainly because of cytoplasmic enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In mid-pregnancy, the lobules further enlarge and increase in number. They surround the duct from which their central branch proceeds so thickly that the chief duct, the terminal or intralobular terminal duct, can no longer be recognized. The transition between the terminal ducts and the budding acini is gradual, making the histological distinction between the two of them difficult; both show evidence of early secretory activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Later pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammary changes during the second half of pregnancy are chiefly a continuation and accentuation of secretory activity. Further progressive branching continues with less prominent bud formation. The formation of fully differentiated secretory units or acini becomes increasingly evident. Proliferation of new acini is reduced, and the lumen of already formed units becomes distended by the accumulation of secretory material or colostrum.",
"   </p>",
"   <p>",
"    Just before and during parturition, there is a new wave of mitotic activity within the mammary gland. At this time, and during lactation, the process of further growth and differentiation may be observed in the same lobule type, side by side with the process of milk secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/3\">",
"     3",
"    </a>",
"    ]. At this point, the glandular component of the breast has increased to the point where the breast is composed primarily of epithelial elements, with very little stroma. These changes persist throughout lactation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Lobular involution (regression)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Postlactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postlactational breast requires a combination of lactogenic hormone deprivation and local signals to undergo glandular involution (regression or atrophy), a process characterized by apoptotic cell death and tissue remodeling. The factors that trigger apoptosis have not been clearly defined. Certain gene products are upregulated during mammary involution, as are local extracellular proteases that are involved in tissue remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Menopause",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menopause supervenes as a consequence of ovarian follicular atresia, resulting in an ovary completely devoid of follicles. This is characterized clinically by the absence of ovarian estradiol and progesterone secretion, resulting in amenorrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15720?source=see_link\">",
"     \"Ovarian development and failure (menopause) in normal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After menopause, the breast undergoes regression, with atrophy of the glandular elements, and a marked decrease in the number of lobules. This process differs greatly from postlactational involution (regression or atrophy). In some areas, the lobules disappear completely, and only the ducts remain. Concurrently, the fibrous connective tissue component of the stroma decreases, and adipose tissue accumulates (",
"    <a class=\"graphic graphic_picture graphicRef77903 \" href=\"UTD.htm?36/47/37619\">",
"     picture 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Microanatomically, involution is manifested by an increasing number of type 1 lobules, and a concomitant decline in the number of type 2 and 3 lobules which, although more marked in parous women, also occurs in nulliparous women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/3,8\">",
"     3,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ABNORMALITIES IN BREAST DEVELOPMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Congenital",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common congenital abnormality of breast development, which can be seen both in boys and girls, is an accessory nipple (polythelia). Ectopic nipple tissue may occur at any point along the milk streak from the axilla to the groin. Rarely, accessory true mammary glands develop, most commonly in the axilla (polymastia). During pregnancy and lactation, an accessory breast may swell, and if an associated nipple is present, it may secrete milk. Polythelia may be associated with renal anomalies and other lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypoplasia refers to underdevelopment of the breast, while congenital absence of the breast is referred to as amastia, and in cases where breast tissue is lacking but a nipple is present, amazia. Unilateral hypoplasia may be accompanied by a normal, hypoplastic, or hyperplastic contralateral breast.",
"   </p>",
"   <p>",
"    The most severe of these deformities, amastia or severe unilateral hypoplasia, is associated with hypoplasia of the pectoral muscle in 90 percent of cases. However, the reverse does not apply; in women with pectoral muscle abnormalities, 92 percent have a normal breast [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/12\">",
"     12",
"    </a>",
"    ]. In Poland sequence, abnormalities ranging from unilateral hypoplasia to absence of the breast and pectoral muscle frequently occur in combination with distal hypoplasia of the upper limb, and anomalies of the hand (syndactyly, brachydactyly, oligodactyly) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. These anomalies may result from diminished blood flow in the subclavian artery during early fetal development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=see_link\">",
"     \"Diseases of the chest wall\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18616726\">",
"    <span class=\"h2\">",
"     Premature thelarche",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early breast development in girls (premature thelarche) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link\">",
"     \"Definition, etiology, and evaluation of precocious puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Acquired",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common and avoidable cause of amazia is iatrogenic: the injudicious biopsy of a precociously developing breast. The use of radiation therapy in prepubertal girls to treat either hemangioma of the breast or intrathoracic disease can also result in amazia. Deformity may also develop in cases of traumatic injury of the developing breast.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     HORMONAL INFLUENCES ON BREAST DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal mammary growth, differentiation, and regression is the result of complex interactions between systemic hormones and local cell-cell interactions, which are mediated by a variety of growth factors, including epidermal growth factor, transforming growth factor, and fibroblast growth factor. The morphologic response of the mammary gland to these complex interactions results in developmental changes that permanently modify both its architecture and biologic characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Estrogens and progesterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogens are considered to play the major role in promoting proliferation of the breast epithelium. Estradiol acts locally on the mammary gland, stimulating DNA synthesis and promoting bud formation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/16\">",
"     16",
"    </a>",
"    ]. These biologic activities are thought to be predominantly mediated by a nuclear estrogen receptor (ER alpha), which activates transcription of specific genes containing the estrogen response elements [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/18\">",
"     18",
"    </a>",
"    ]. The importance of ER-alpha is reflected in the poorly developed mammary glands of knockout mice who are ER-alpha (but not ER-beta)-null [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal ductal development requires both estrogen and progesterone. Progesterone acts in conjunction with estrogen to regulate breast development through its specific receptor (PR) on breast epithelial cells. As evidence of the importance of progesterone, during the normal menstrual cycle, the breast epithelium does not exhibit maximal proliferation during the follicular phase, when estrogen secretion is at its peak, but instead, during the luteal phase, when progesterone levels are at their highest, and estrogen levels have begun to decline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=see_link\">",
"     \"Physiology of the normal menstrual cycle\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cell proliferation and hormone receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proliferative activity of the mammary epithelium varies with the degree of lobular differentiation. In humans, the highest level of proliferative activity is observed in the undifferentiated type 1 lobule, present in the breast of young nulliparous females [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/8,16,17,20\">",
"     8,16,17,20",
"    </a>",
"    ]. With progressive differentiation into type 2 and 3 lobules under the hormonal influences of the menstrual cycle, there is a concomitant reduction in proliferative activity. Compared to the cells comprising type 1 lobules, the rate of cellular proliferation, as determined by the percentage of cells that stain positively with Ki-67, is decreased 3-fold in the type 2 lobules, and 10-fold in the type 3 lobules (",
"    <a class=\"graphic graphic_table graphicRef61091 \" href=\"UTD.htm?25/34/26156\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/17,21\">",
"     17,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The content of ER-alpha and PR in the lobular structures of the breast is directly proportional to the rate of cellular proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/21\">",
"     21",
"    </a>",
"    ]. Type 1 lobules consistently contain a higher percentage of ER and PR-positive cells than do type 2 or 3 lobules, indicating a progressive decease in the number of receptor-positive cells as the structures become more differentiated (",
"    <a class=\"graphic graphic_table graphicRef61091 \" href=\"UTD.htm?25/34/26156\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These biologic differences may have profound implications for cancer risk. The fact that the highest proliferative capacity and the highest percentage of ER-alpha- and PR-positive cells are present in type 1 lobules provides a mechanistic explanation for the greater susceptibility of these structures to be transformed by chemical carcinogens in vitro and in experimental animals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/2,22-28\">",
"     2,22-28",
"    </a>",
"    ], and supports the observation that type 1 lobules are the site of origin of ductal carcinomas (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Cancer risk'",
"    </a>",
"    below). The proliferating cells differ from those that are receptor-positive, suggesting that the proliferative influence of estrogen on the breast epithelium is indirect [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PARITY, LOBULAR DIFFERENTIATION AND BREAST CANCER RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;By the end of their 40s, the breast of both nulliparous and parous women is composed predominantly of type 1 lobules [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/8\">",
"     8",
"    </a>",
"    ]. However, despite their architectural similarity, there are important differences between the type 1 lobules of the nulliparous woman, and the regressed type 1 lobules of the parous woman. Type 1 lobules of nulliparous women have a very active intralobular stroma, whereas those of the parous woman are more hyalinized, and indicative of a regressed structure. Another important difference is the higher proliferative activity in the type 1 lobules of nulliparous as compared to parous women. The cells of both type 1 and type 3 lobules in the parous breast are predominantly in the G0 phase or resting phase, while in type 1 lobules of the nulliparous breast, proliferating cells predominate, and the fraction of cells in G0 is quite low. Thus, parity, in addition to exerting an important influence on the lobular composition of the breast, profoundly influences its proliferative activity.",
"   </p>",
"   <p>",
"    These biologic differences may provide some explanation for the increased susceptibility of the breast of nulliparous women to develop breast cancer. It is hypothesized that unlike parous women, the type 1 lobule found in the breast of nulliparous women never went through the process of differentiation, seldom reaching the type 3 lobule, and never the type 4 stages [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/8\">",
"     8",
"    </a>",
"    ]. Although the lobules of parous women regress at menopause to type 1, they are permanently genetically imprinted by the differentiation process in some way that protects them from neoplastic transformation, even though these changes are no longer morphologically observable. Thus, they are biologically different from the type 1 lobule of nulliparous women.",
"   </p>",
"   <p>",
"    The postulated mechanism of protection conferred by early full term pregnancy is that the degree of differentiation acquired through early pregnancy changes the \"genomic signature\" that differentiates the type 1 lobule from the early parous women from that of the nulliparous women by shifting the stem cell population from \"stem cell 1\" to \"stem cell 2\". The genomic signature of the stem cell 2 differs from that of the stem cell 1 cells, and the specific gene products synthesized by the stem cell 2 population can be detected in the blood after the pregnancy event is over [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Detection of these gene products in circulating blood indicates that the breast has completed the process of differentiation, thus serving as an indicator of the presence of a protective factor, namely, a surrogate marker of lower susceptibility to develop cancer in early parous women. The pattern of gene expression of the stem cell 2 could potentially be used as useful intermediate end points for evaluating the degree of mammary gland differentiation and for evaluating preventive agents like human chorionic gonadotropin.",
"   </p>",
"   <p>",
"    The extent of age-related menopausal involution (regression or atrophy) of the type 1 lobule appears to influence the risk of breast cancer, and may modify other breast cancer risk factors, including parity. It has also been postulated that unresponsive lobules that fail to undergo differentiation under the stimulus of pregnancy and lactation are responsible for cancer development despite the parity history [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for these observations were provided in a report that focused on breast biopsy specimens from 8736 women with benign breast disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/34\">",
"     34",
"    </a>",
"    ]. The authors characterized the degree of involution (regression) of both the terminal duct lobular units (type 1 lobules) and the atrophic or involuted structures that result from the normal process of aging in the human breast. They defined complete involution as &ge;75 percent of the lobules involuted, partial involution as 1 to 74 percent involuted; and none as 0 percent involuted. The relative risk of breast cancer was estimated based upon standardized incidence ratios by dividing the observed numbers of incident breast cancers by expected values of population based incident breast cancers from the Iowa Surveillance, Epidemiology and End Results (SEER) registry.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of breast cancer was significantly higher for women with no involution, compared to those with partial or complete involution (relative risks [RRs] 1.88, 1.47, and 0.91, respectively).",
"     </li>",
"     <li>",
"      The degree of involution modified the risk of developing breast cancer in women who had atypia in their breast biopsies (RR 7.79, 4.06, and 1.49 for women with none, partial, and complete involution, respectively) as well as for those with proliferative disease without atypia (RR 2.94 and 1.11 for those with no and complete involution, respectively).",
"     </li>",
"     <li>",
"      There was an interaction with family history as well; women with a weak or no family history of breast cancer who had complete involution had a risk for breast cancer that was five-fold lower than the risk of those with a strong family history and no involution (RR 0.59 versus 2.77, respectively).",
"     </li>",
"     <li>",
"      Among nulliparous women, and those whose age at first birth was over the age of 30, the absence of involution significantly increased the risk of breast cancer (RR 2.41 versus 2.74, respectively). In contrast; for both groups, there was no excess risk if involution was complete.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent studies confirm that the degree of lobular involution is inversely associated with breast cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. A nested case-control study of lobule involution used the number of acini per lobule as a reflection of the degree of involution and compared acinar counts in women who did or did not go on to develop breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/35\">",
"     35",
"    </a>",
"    ]. Women with no involution had a higher mean acinar count (32",
"    <span class=\"nowrap\">",
"     acini/lobule)",
"    </span>",
"    than women with partial (19.7",
"    <span class=\"nowrap\">",
"     acini/lobule)",
"    </span>",
"    or complete involution (7.7",
"    <span class=\"nowrap\">",
"     acini/lobule).",
"    </span>",
"    There was a step-wise increase in breast cancer risk with increasing numbers of acini and decreasing degree of involution per lobule. Another study assessed lobule type rather than the degree of involution but arrived at a similar conclusion; women with more type 1 lobules, with more complete involution, have a lower breast cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Taken together, these data suggest that breast cancer risk is decreased in women with more type 1 lobules and more complete involution (regression) of lobular structures. This reflects parity and terminal differentiation of lobules and helps to explain why pregnancy and lactation seem to decrease the risk of breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/32\">",
"     32",
"    </a>",
"    ]. This data also raises concerns that reactivation of type 1 lobules, as has been described in women receiving postmenopausal hormone therapy who develop dense breasts, may increase the risk of developing breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ARCHITECTURAL PATTERNS AND BREAST PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fact that the mature breast exhibits variations in development, proliferative activity, and hormone receptor content raises the question of whether benign, premalignant,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    malignant breast lesions develop as a reflection of these variations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Proliferative lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of breast development appears to be important in the susceptibility to proliferative influences [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/38\">",
"     38",
"    </a>",
"    ]. One study compared the pattern of lobular development in breast tissues devoid of mammary pathology (33 reduction mammoplasties performed in both parous and nulliparous women) with that of 45 noncancerous breast biopsies performed because of mammographic abnormalities or clinically suspicious findings [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/38\">",
"     38",
"    </a>",
"    ]. The patient populations were then subdivided according to parity status. Despite the absence of cancer, tissues obtained from breast biopsies had an architectural pattern that differed markedly from those obtained from reduction mammoplasties for women of comparable parity status. Parous women who underwent a breast biopsy had a significantly higher percentage of type 1 lobules (65 versus 17 percent) and a lower percentage of type 3 lobules (14 versus 48 percent) than did the parous population of the reduction mammoplasty group.",
"   </p>",
"   <p>",
"    When the groups were subdivided according to histologic diagnosis, (21 normal breast, 15 ductal hyperplasia [DH], four with blunt duct adenosis [BDA], and five with sclerosing adenosis [SAD]), and the tissues analyzed for lobular architecture, lesion type, and proliferative rate, breast tissue classified as normal or DH had a significantly higher percentage of type 1 lobules, while the SAD group had a significantly higher percentage of type 2 lobules. Furthermore, the number of proliferating cells was highest in the type 1 lobules for all tissues except BDA, in which the proliferative rate was highest in type 2 lobules. From these data, the following conclusions were drawn:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breast tissues obtained from biopsies performed because of mammographic or clinical abnormalities (even in the absence of cancer) have architectural and cell kinetic patterns that differ from tissues obtained at reduction mammoplasties. Even in cases where pathology was absent or was benign, the pattern of breast development was more similar to that of a cancer-bearing breast than it was to the population not requiring biopsy.",
"     </li>",
"     <li>",
"      In DH, type 1 lobules are the most frequent structures present, and they have the highest proliferative rate, supporting the postulate that this lesion arises from type 1 lobules. In contrast, type 2 and 3 lobules are more prominently represented, and have a higher proliferative rate in more differentiated lesions, such as BDA and SAD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several lines of evidence support the type 1 lobule as being the equivalent of the terminal ductal lobular unit [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], and the site of origin of ductal carcinomas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In autopsy studies, the nontumoral parenchyma of breasts harboring a malignancy contains a significantly higher number of hyperplastic terminal ducts, atypical type one lobules, and ductal carcinoma in situ (DCIS) originating from type 1 lobule compared to those breasts that are free of malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/22,33\">",
"       22,33",
"      </a>",
"      ]. Thus, the type 1 lobule is affected by both preneoplastic and neoplastic processes.",
"     </li>",
"     <li>",
"      Although the breast tissue from parous women in the general population contains predominantly type 3 lobule, and a very low percentage of type 1 lobules, the nontumoral breast tissue of parous women who have developed breast cancer (all of whom had a late first pregnancy or a family history of breast cancer in our studies) consist of predominantly type 1 lobules [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/33,41\">",
"       33,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The architectural pattern of nonmalignant breast tissue in parous women undergoing mastectomy for invasive breast cancer, or prophylactic mastectomy because of a genetic predisposition to breast cancer differs from that of women undergoing reduction mammoplasties, with a predominance of type 1 lobules, regardless of parity [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/8,32\">",
"       8,32",
"      </a>",
"      ]. These observations suggest that genetic predisposition to breast cancer might affect genes that control the branching pattern of the breast during lobular development.",
"     </li>",
"     <li>",
"      The type 1 lobules are most numerous in the breasts of nulliparous women, who are at a higher risk of breast cancer than parous women [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Menopause'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More differentiated lobular structures, such as type 2 lobules, are affected by other types of neoplastic lesions, notably lobular carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Defective regulation of epithelial growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular mechanisms underlying the development of breast cancer, particularly estrogen-associated carcinogenesis, are incompletely understood. It is generally believed that the initiation of breast cancer results from uncontrolled cellular proliferation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aberrant apoptosis as a consequence of cumulative genetic damages that activate protooncogenes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inactivate tumor suppressor genes. These genetic alterations can be inherited as germline mutations, or be acquired (somatic mutations) as a result of cumulative exposure to environmental carcinogens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    .) The classic two-stage model of carcinogenesis further postulates that the altered genotype of the initiated cell is irreversible, and that tumor progression, the second stage in carcinogenesis, depends upon further epigenetic changes that are potentially reversible.",
"   </p>",
"   <p>",
"    It remains to be determined whether this animal model of chemical carcinogenesis holds true for breast cancer, and what role is played by estrogen. In rodent models of carcinogen-induced and spontaneous mammary cancer, prolonged exposure to both estrogens and progestins can support initial tumor formation and early tumor growth. In vitro, 17-beta estradiol induces phenotypic changes indicative of neoplastic transformation in cultured human breast epithelial cells that are similar to those induced by the chemical carcinogen benz[a]pyrene [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/42\">",
"     42",
"    </a>",
"    ]. Furthermore, human studies now provide a clear link between exposure to exogenous hormones and a risk for breast cancer (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although some breast cancers may be related to cumulative hormonal exposures, others, particularly those with an inherited genetic susceptibility, may be caused by an unusual sensitivity to pubertal hormones. As an example, in a case-control study of disease-concordant monozygotic twins, the twin with earlier onset of menses was five times more likely to be diagnosed with breast cancer before the other [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/43\">",
"     43",
"    </a>",
"    ]. In contrast, other hormonal factors (ie, later first pregnancy, lower parity, later menopause) did not predict an earlier diagnosis when both twins were affected. These data suggest that genotypic differences exist, even among patients with an inherited genetic susceptibility.",
"   </p>",
"   <p>",
"    Even though the cause of breast cancer and the ultimate mechanisms through which an early pregnancy protects from cancer development remain largely unknown, comparative studies of normal and neoplastic breast development have unraveled similarities with experimental models that validate their extrapolation for testing hypotheses on the initiation and progression of human breast cancer. From these studies the following can be concluded:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The process of mammary gland differentiation is the result of complex interactions of ovarian, pituitary, and placental hormones, which in turn induce inhibition of cell proliferation, downregulation of ER and PR receptors, activation of specific genes and expression of extracellular matrix proteins in the normal breast. Findings in experimental animal models indicate that induction of mammary cancer with chemical carcinogens is only successful when the carcinogen interacts with an undifferentiated and highly proliferating mammary epithelium, whereas differentiation of the mammary gland inhibits carcinogenic initiation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/17,44\">",
"       17,44",
"      </a>",
"      ]. These data support the view that breast cancer arises in women whose breasts have failed to achieve an optimal degree of differentiation.",
"     </li>",
"     <li>",
"      Cellular susceptibility to transformation by estrogens may depend more on proliferative rate and genetic predisposition rather than hormone receptor content, similar to what has been observed with chemical carcinogenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/25,45,46\">",
"       25,45,46",
"      </a>",
"      ]. The independence of ER content and estrogen-induced carcinogenesis would support the postulate that metabolic activation of estrogen is involved in the neoplastic transformation of susceptible breast epithelial cells. Alternatively, estrogen",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      its metabolites may act instead to promote neoplastic progression in chemically transformed breast epithelial cells.",
"     </li>",
"     <li>",
"      In experimental animals, the protective effect exerted by pregnancy on mammary carcinogenesis can be mimicked by treatment with the placental hormone chorionic gonadotropin. These data open the possibility of preventing breast cancer by treating young nulliparous females with hormones that mimic a full term pregnancy, inducing complete differentiation of the gland [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Particularly in view of the fact that the terminal ductal lobular units are thought to represent the site of origin of mammary carcinomas, partial or incomplete menopausal breast involution (or reactivation of type 1 lobules under the influence of postmenopausal hormone therapy) may also interact with other risk factors such as parity, age at first birth, the presence of benign breast disease, and family history to influence the risk of breast cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20649/abstract/32,34\">",
"       32,34",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Parity, lobular differentiation and breast cancer risk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=see_link\">",
"       \"Patient information: Normal sexual development (puberty) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/58/31650?source=see_link\">",
"       \"Patient information: Early puberty (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/31/13810?source=see_link\">",
"       \"Patient information: Late puberty (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human breast development is a progressive process that is initiated during embryonic life. Although puberty marks the beginning of glandular maturation, full breast differentiation is attained only with subsequent pregnancy and lactation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Normal development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast tissue is composed of both epithelial and stromal elements. The epithelial components are branching ducts which connect the structural and functional units of the breast (the lobules) to the nipple. The stroma, which comprises the majority of the breast volume in the non-lactating state, is composed of adipose and fibrous connective tissue. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principal blood supply of the breast is derived from the internal mammary artery. Approximately one-third of the blood supply (mainly to the upper outer quadrant) is provided by the lateral thoracic arteries. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lymph flow from the deep subcutaneous and intramammary vessels moves centrifugally toward the axillary and internal mammary lymph nodes. The majority (97 percent) of the lymph flows to the axillary nodes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During pregnancy, the maximum branching capability of the breast is expressed, and the secretory acinus that is formed during pregnancy represents a terminal outgrowth that marks the full extent of glandular differentiation. Fully differentiated secretory cells are characterized by their ability to synthesize and secrete milk proteins and lipids. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pregnancy and lactation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The postlactational breast requires a combination of lactogenic hormone deprivation and local signals to undergo glandular regression (involution), a process characterized by apoptotic cell death and tissue remodeling. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pregnancy and lactation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After menopause, the breast undergoes regression, with atrophy of the glandular elements, and a marked decrease in the number of lobules. Concurrently, the fibrous connective tissue component of the stroma decreases, and adipose tissue accumulates. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Menopause'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parity influences the lobular composition as well as the proliferative activity of the breast. The lobules of nulliparous women have a higher proliferative activity than those of parous women. These differences may influence the risk of developing breast cancer. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Menopause'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normal ductal development requires both estrogen and progesterone. Progesterone acts in conjunction with estrogen to regulate breast development through its specific receptor on breast epithelial cells. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Hormonal influences on breast development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The extent of breast involution appears to influence the risk of breast cancer, and may modify other breast cancer risk factors, including parity. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Parity, lobular differentiation and breast cancer risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast disease may develop in response to variations in development, proliferative activity, and hormone receptor content in the mature breast. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Architectural patterns and breast pathology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/1\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/2\">",
"      Russo IH, Russo J. Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 1996; 104:938.",
"     </a>",
"    </li>",
"    <li>",
"     Russo, J, Russo, IH. In: The Mammary Gland, Neville, MC, Daniel, CW, (Eds), Plenum Publishing Corporation, New York 1987. p.67.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/4\">",
"      Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1988; 48:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/5\">",
"      Cummings SR, Duong T, Kenyon E, et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 2002; 287:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/6\">",
"      HULTBORN KA, LARSSON LG, RAGNHULT I. The lymph drainage from the breast to the axillary and parasternal lymph nodes, studied with the aid of colloidal Au198. Acta radiol 1955; 43:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/7\">",
"      Byrd DR, Dunnwald LK, Mankoff DA, et al. Internal mammary lymph node drainage patterns in patients with breast cancer documented by breast lymphoscintigraphy. Ann Surg Oncol 2001; 8:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/8\">",
"      Russo J, Rivera R, Russo IH. Influence of age and parity on the development of the human breast. Breast Cancer Res Treat 1992; 23:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/9\">",
"      Strange R, Li F, Saurer S, et al. Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development 1992; 115:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/10\">",
"      Jhappan C, Geiser AG, Kordon EC, et al. Targeting expression of a transforming growth factor beta 1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J 1993; 12:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/11\">",
"      Lewis EJ, Crutchfield CE 3rd, Ebertz MJ, Prawer SE. Report of a nipple nevus and an overview of accessory mammary tissue. Cutis 1998; 62:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/12\">",
"      Trier, WC. Complete breast absence. Plast Reconstruct Surg 1965; 36:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/13\">",
"      Ravitch, MM. Poland's syndrome: A study of an eponym. Plast Reconstr Surg 1977; 59:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/14\">",
"      Beals RK, Crawford S. Congenital absence of the pectoral muscles. A review of twenty-five patients. Clin Orthop Relat Res 1976; :166.",
"     </a>",
"    </li>",
"    <li>",
"     Jones, KL. Smith's Recognizable Patterns of Human Malformation, 5th ed, WB Saunders, Philadelphia, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/16\">",
"      Russo IH, Russo J. Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 1998; 3:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/17\">",
"      Russo J, Hu YF, Silva ID, Russo IH. Cancer risk related to mammary gland structure and development. Microsc Res Tech 2001; 52:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/18\">",
"      King RJ. Effects of steroid hormones and related compounds on gene transcription. Clin Endocrinol (Oxf) 1992; 36:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/19\">",
"      Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 1999; 20:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/20\">",
"      Russo J, Russo IH. Influence of differentiation and cell kinetics on the susceptibility of the rat mammary gland to carcinogenesis. Cancer Res 1980; 40:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/21\">",
"      Russo J, Ao X, Grill C, Russo IH. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 1999; 53:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/22\">",
"      Russo J, Gusterson BA, Rogers AE, et al. Comparative study of human and rat mammary tumorigenesis. Lab Invest 1990; 62:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/23\">",
"      Russo J, Calaf G, Russo IH. A critical approach to the malignant transformation of human breast epithelial cells with chemical carcinogens. Crit Rev Oncog 1993; 4:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/24\">",
"      Tay LK, Russo J. Formation and removal of 7,12-dimethylbenz[a]anthracene--nucleic acid adducts in rat mammary epithelial cells with different susceptibility to carcinogenesis. Carcinogenesis 1981; 2:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/25\">",
"      Russo J, Reina D, Frederick J, Russo IH. Expression of phenotypical changes by human breast epithelial cells treated with carcinogens in vitro. Cancer Res 1988; 48:2837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/26\">",
"      Russo J, Mills MJ, Moussalli MJ, Russo IH. Influence of human breast development on the growth properties of primary cultures. In Vitro Cell Dev Biol 1989; 25:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/27\">",
"      Tay LK, Russo J. In vitro metabolism of 7,12-dimethylbenz[a]anthracene in mammary epithelial cells from rats with different susceptibilities to carcinogenesis. Carcinogenesis 1983; 4:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/28\">",
"      Russo J, Russo IH. Susceptibility of the mammary gland to carcinogenesis. II. Pregnancy interruption as a risk factor in tumor incidence. Am J Pathol 1980; 100:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/29\">",
"      Balogh GA, Heulings R, Mailo DA, et al. Genomic signature induced by pregnancy in the human breast. Int J Oncol 2006; 28:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/30\">",
"      Balogh GA, Russo IH, Spittle C, et al. Immune-surveillance and programmed cell death-related genes are significantly overexpressed in the normal breast epithelium of postmenopausal parous women. Int J Oncol 2007; 31:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/31\">",
"      Balogh GA, Heulings R, Mailo D, et al. Methodological approach to study the genomic profile of the human breast. Int J Oncol 2007; 31:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/32\">",
"      Russo J, Lynch H, Russo IH. Mammary gland architecture as a determining factor in the susceptibility of the human breast to cancer. Breast J 2001; 7:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/33\">",
"      Russo J, Romero AL, Russo IH. Architectural pattern of the normal and cancerous breast under the influence of parity. Cancer Epidemiol Biomarkers Prev 1994; 3:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/34\">",
"      Milanese TR, Hartmann LC, Sellers TA, et al. Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 2006; 98:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/35\">",
"      McKian KP, Reynolds CA, Visscher DW, et al. Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol 2009; 27:5893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/36\">",
"      Baer HJ, Collins LC, Connolly JL, et al. Lobule type and subsequent breast cancer risk: results from the Nurses' Health Studies. Cancer 2009; 115:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/37\">",
"      Harvey JA, Santen RJ, Petroni GR, et al. Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. Menopause 2008; 15:67.",
"     </a>",
"    </li>",
"    <li>",
"     Russo, J, Russo, IH. Differentiation and breast cancer development. In: Advances in Oncobiology, vol 2, Heppner, G, (Ed), Jai Press, London, 1998. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/39\">",
"      Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975; 55:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/40\">",
"      Wellings SR. Development of human breast cancer. Adv Cancer Res 1980; 31:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/41\">",
"      Russo J, Russo IH. Development pattern of human breast and susceptibility to carcinogenesis. Eur J Cancer Prev 1993; 2 Suppl 3:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/42\">",
"      Russo J, Lareef MH, Tahin Q, et al. 17Beta-estradiol is carcinogenic in human breast epithelial cells. J Steroid Biochem Mol Biol 2002; 80:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/43\">",
"      Hamilton AS, Mack TM. Puberty and genetic susceptibility to breast cancer in a case-control study in twins. N Engl J Med 2003; 348:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/44\">",
"      Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982; 2:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/45\">",
"      Calaf G, Russo J. Transformation of human breast epithelial cells by chemical carcinogens. Carcinogenesis 1993; 14:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/46\">",
"      Hu YF, Russo IH, Zalipsky U, et al. Environmental chemical carcinogens induce transformation of breast epithelial cells from women with familial history of breast cancer. In Vitro Cell Dev Biol Anim 1997; 33:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/47\">",
"      Russo J, Russo IH. Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomarkers Prev 1994; 3:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20649/abstract/48\">",
"      Russo IH, Koszalka M, Russo J. Human chorionic gonadotropin and rat mammary cancer prevention. J Natl Cancer Inst 1990; 82:1286.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 812 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_10_20649=[""].join("\n");
var outline_f20_10_20649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Blood supply and lymphatic drainage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NORMAL DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pubertal changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lobule formation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Type 1 lobules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Type 2 and 3 lobules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Type 4 lobules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Early pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Later pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Lobular involution (regression)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Postlactation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ABNORMALITIES IN BREAST DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Congenital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18616726\">",
"      Premature thelarche",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Acquired",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      HORMONAL INFLUENCES ON BREAST DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Estrogens and progesterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cell proliferation and hormone receptors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PARITY, LOBULAR DIFFERENTIATION AND BREAST CANCER RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ARCHITECTURAL PATTERNS AND BREAST PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Proliferative lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cancer risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Defective regulation of epithelial growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/812\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/812|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/34/8744\" title=\"figure 1\">",
"      Lymphatic drainage of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/812|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/47/17145\" title=\"picture 1\">",
"      Histology normal breast tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/43/10932\" title=\"picture 2\">",
"      Sexual maturity rating of breast development in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/39/38517\" title=\"picture 3\">",
"      Type 1 breast lobule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/54/9060\" title=\"picture 4\">",
"      Type 2 breast lobule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/24/13699\" title=\"picture 5\">",
"      Type 3 breast lobule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/40/23174\" title=\"picture 6\">",
"      Type 4 breast lobule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/47/37619\" title=\"picture 7\">",
"      Atrophy breast tissue menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/812|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/47/14075\" title=\"table 1\">",
"      Breast lobules differences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/34/26156\" title=\"table 2\">",
"      Prolif rate recept breast tiss",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13274?source=related_link\">",
"      Maternal endocrine and metabolic adaptation to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41672?source=related_link\">",
"      Molecular biology and physiology of estrogen action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15720?source=related_link\">",
"      Ovarian development and failure (menopause) in normal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/58/31650?source=related_link\">",
"      Patient information: Early puberty (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/31/13810?source=related_link\">",
"      Patient information: Late puberty (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=related_link\">",
"      Patient information: Normal sexual development (puberty) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=related_link\">",
"      Physiology of gonadotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6519?source=related_link\">",
"      Physiology of lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_10_20650="Regulation of erythropoiesis";
var content_f20_10_20650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Regulation of erythropoiesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/10/20650/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/10/20650/contributors\">",
"     Colin A Sieff, MB, BCh, FRCPath",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/10/20650/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/10/20650/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/10/20650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/10/20650/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/10/20650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The production of erythrocytes is a tightly regulated process. During steady state hematopoiesis, approximately 10",
"    <sup>",
"     10",
"    </sup>",
"    red blood cells are produced per hour in the bone marrow to maintain the hemoglobin level within fairly narrow limits. Production can be rapidly increased in the setting of ongoing blood loss or hemolysis.",
"   </p>",
"   <p>",
"    Erythropoiesis begins with the differentiation of a small pool of pluripotent stem cells into the most primitive erythroid progenitors. These progenitors develop into recognizable erythroid precursors, which subsequently follow a specific differentiation program that culminates in the emergence of mature erythrocytes. This process is driven by successive combinations of transcription factors that dictate the expression of adhesion and hematopoietic growth factor receptors (HGFRs):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adhesion receptors play an important role in the localization and release of maturing cells from specific niches in bone marrow.",
"     </li>",
"     <li>",
"      Hematopoietic growth factors (HGFs), such as those for interleukin 3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), and Stem Cell Factor (SCF, also called c-kit ligand or Steel factor), are important for the amplification of progenitor cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Erythropoietin (EPO) is a growth factor essential for the amplification and terminal differentiation of erythroid progenitors and precursors. Information concerning the control of EPO expression by hypoxia has provided new insight into the regulation of erythropoiesis. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Hypoxia and EPO expression'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=see_link&amp;anchor=H4#H4\">",
"     \"Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera\", section on 'Oxygen sensor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the elements that underlie erythropoiesis. A general discussion of hematopoiesis and stem cell function is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ERYTHROID PROGENITOR CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The erythroid progenitor compartment of the bone marrow is invisible upon inspection by light microscopy. These committed single lineage progenitors are derived from the stochastic differentiation of bipotential or multipotential progenitors, which emerged from a tiny population of stem cells (",
"    <a class=\"graphic graphic_figure graphicRef70092 \" href=\"UTD.htm?12/31/12799\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, the most primitive single lineage committed erythroid progenitor is the erythroid burst-forming unit (BFU-E). These cellular clusters are so named because they have the following characteristics in semisolid in vitro cultures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The colonies have a burst-like morphology.",
"     </li>",
"     <li>",
"      In response to the combination of EPO and one of SCF, IL-3, or GM-CSF, the progeny of the first few cellular divisions are motile and form subpopulations of erythroid colony-forming units (CFU-E) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/2\">",
"       2",
"      </a>",
"      ]. Each of these units subsequently forms a large colony of proerythroblasts, which become more mature erythroblasts and a few enucleated reticulocytes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The entire process requires approximately two weeks in vitro.",
"   </p>",
"   <p>",
"    Bone marrow also contains the more mature CFU-E that, under the influence of EPO, form small colonies of erythroblasts in seven days. These two sets of erythroid progenitors (BFU-E and CFU-E) cannot be identified by specific morphological features. Evidence suggests that all hematopoietic progenitors or stem cells resemble lymphoblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRECURSORS AND MATURE CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The erythroid precursor or erythroblast pool represents about one-third of the marrow cell population in the normal child (above the age of three) and the adult. Proerythroblasts are the earliest recognizable forms (",
"    <a class=\"graphic graphic_picture graphicRef68933 \" href=\"UTD.htm?39/7/40050\">",
"     picture 1",
"    </a>",
"    ). These cells divide and mature through basophilic, polychromatic, and orthochromatic normoblast cells to form the reticulocyte and finally to the circulating mature erythrocyte; this process involves a reduction in cell size, nuclear condensation and extrusion, and hemoglobin accumulation (",
"    <a class=\"graphic graphic_figure graphicRef55127 \" href=\"UTD.htm?2/44/2752\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On average, each proerythroblast can form approximately eight reticulocytes. The mean transit time from proerythroblast to the emergence of the reticulocyte into the circulation is approximately five days [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Once in the circulation, the reticulocyte takes approximately one day to become the mature erythrocyte (",
"      <a class=\"graphic graphic_figure graphicRef61552 \" href=\"UTD.htm?32/34/33325\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link&amp;anchor=H6#H6\">",
"       \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Reticulocyte response'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The lifespan in the circulation of the mature erythrocyte is approximately four months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36326?source=see_link&amp;anchor=H19582914#H19582914\">",
"       \"Red blood cell survival: Normal values and measurement\", section on 'Normal RBC lifespan'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In acute anemia, the length of this transit time may decrease to as little as one or two days because of skipped divisions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/7\">",
"     7",
"    </a>",
"    ]. In this setting, the red cells that emerge are macrocytic; they may also bear surface i antigen and other fetal characteristics because they have had insufficient time to have converted i antigen to I antigen or to have acquired other adult characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/8\">",
"     8",
"    </a>",
"    ]. The cells also contain excessive burdens of the debris that normally accumulates during cell assembly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. As a result, stress erythropoiesis is associated with circulating Pappenheimer bodies (iron granules), basophilic stippling (ribosomes), Heinz bodies (hemoglobin inclusions), and Howell-Jolly bodies (nuclear remnants) (",
"    <a class=\"graphic graphic_picture graphicRef71989 graphicRef73790 graphicRef60588 \" href=\"UTD.htm?39/37/40538\">",
"     picture 2A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     STROMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone marrow stroma consists of fibroblastoid cells, endothelial cells, and macrophages that comprise the hematopoietic microenvironment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Interaction between receptors on erythrocyte precursors and elements of the stromal matrix are important determinants of erythroid maturation. As an example, murine erythroleukemia cells bind specifically to the extracellular matrix protein fibronectin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/13\">",
"     13",
"    </a>",
"    ]; induction of differentiation of these cells subsequently leads to loss of adhesion. Binding to fibronectin involves very late antigen (VLA)-5, an erythroid integrin that is expressed on erythroid cells and is lost at the reticulocyte stage of development. VLA-5 binds to a specific peptide in the fibronectin molecule, Arg-Gly-Asp-Ser (RGDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal BFU-E bind preferentially to a stromal fibroblast cell strain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/15\">",
"     15",
"    </a>",
"    ]; after binding, these cells proliferate and differentiate in the presence of EPO alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/15\">",
"     15",
"    </a>",
"    ]. This interaction is blocked by antibodies specific for the cell binding domain of fibronectin, which contains the RGDS sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/15\">",
"     15",
"    </a>",
"    ]. Interactions between developing erythroid cells and macrophages or other stromal cells may also be important [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. This is classically exemplified by the \"erythroblastic island\", composed of developing erythroblasts surrounding a central macrophage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/21\">",
"     21",
"    </a>",
"    ]. Deoxyribonuclease II from these macrophages may be required for the process through which mature red cells lose their nuclei [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TRANSCRIPTION FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much has been learned about the essential roles of several transcription factors via the study of their activation in leukemic translocations and the effect of gene disruption in embryonic stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/23\">",
"     23",
"    </a>",
"    ]. Important factors that most likely act at the level of hematopoietic stem cells include",
"    <span class=\"nowrap\">",
"     Tal-1/SCL,",
"    </span>",
"    <span class=\"nowrap\">",
"     Rbtn2/LMO2,",
"    </span>",
"    and GATA2, while GATA1, FOG-1 and EKLF are more important for erythropoiesis",
"    <span class=\"nowrap\">",
"     (",
"     <a class=\"graphic graphic_figure graphicRef70092 \" href=\"UTD.htm?12/31/12799\">",
"      figure 1",
"     </a>",
"     ).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Tal-1/SCL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tal-1/SCL",
"    is expressed in leukemias (biphenotypic",
"    <span class=\"nowrap\">",
"     [lymphoid/myeloid]",
"    </span>",
"    and T cell) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], primitive hematopoietic progenitors, and more mature erythroid, mast, megakaryocyte, and endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Targeted disruption of this gene in mice leads to death in utero from the absence of blood formation. This finding, together with lack of in vitro myeloid colony formation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], and data indicating that",
"    <span class=\"nowrap\">",
"     Tal-1/SCL",
"    </span>",
"    contribute to angiogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/30\">",
"     30",
"    </a>",
"    ], suggest a very early role for",
"    <span class=\"nowrap\">",
"     Tal-1/SCL,",
"    </span>",
"    most likely at the pluripotent or myeloid-erythroid stem cell level. Interestingly, conditional gene targeting in adult mice shows that",
"    <span class=\"nowrap\">",
"     Tal-1/SCL",
"    </span>",
"    is not required for engraftment and self renewal of adult stem cells, but is required for differentiation of erythroid and megakaryocyte lineages [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/31\">",
"     31",
"    </a>",
"    ]. Overexpression of this factor in erythroid or bipotent cell lines produces an increase in erythroid differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], but there are no data on overexpression in adult hematopoietic stem cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Rbtn2/LMO2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another transcription factor implicated in T cell acute lymphoblastic leukemia is the LIM-only domain nuclear protein rhombotin 2",
"    <span class=\"nowrap\">",
"     (Rbtn2/LMO2)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Mice that lack this factor die in utero and have the same bloodless phenotype as animals that lack",
"    <span class=\"nowrap\">",
"     Tal-1/SCL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/36\">",
"     36",
"    </a>",
"    ]. Although LMO2 does not show sequence specific DNA binding, immunoprecipitates in erythroid cells reveal that LMO2 exists in a complex with",
"    <span class=\"nowrap\">",
"     Tal-1/SCL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], thereby suggesting a physiologic interaction in vivo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     GATA-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;GATA-2 is expressed in the regions of Xenopus and Zebrafish embryos that are fated to become hematopoietic, and is highly expressed in progenitor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/27,39-41\">",
"     27,39-41",
"    </a>",
"    ]. Overexpression of GATA-2 in chicken erythroid progenitors leads to proliferation at the expense of differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, targeted disruption of the GATA-2 gene leads to reduced primitive hematopoiesis in the yolk sac and embryonic death by day 10 to 11 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/43\">",
"     43",
"    </a>",
"    ]. Definitive hematopoiesis in liver and bone marrow is profoundly reduced with loss of virtually all lineages, and in vitro differentiation data reveal a marked deficiency of SCF-responsive definitive erythroid and mast cell colonies and reduced macrophage colonies. This finding suggests that GATA-2 serves as a regulator of genes that control hematopoietic growth factor responsiveness or proliferation of stem",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    early progenitor cells.",
"   </p>",
"   <p>",
"    The finding of markedly decreased expression of GATA-2 mRNA in CD34+ cells in patients with aplastic anemia suggests that an aberrant expression of this transcription factor may be responsible for development of this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/44\">",
"     44",
"    </a>",
"    ]. Alternatively, the reduced levels of GATA-2 could reflect loss of stem cells; it will be important to measure expression in the subset of CD34+ cells enriched for stem cell activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     GATA-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;GATA-1 expression is limited to multipotent progenitors and to erythroid, megakaryocyte, mast, and eosinophil lineages [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Analysis of chimeric mice injected at the blastocyst stage with GATA-1",
"    <span class=\"nowrap\">",
"     -/-",
"    </span>",
"    embryonic stem cells reveals a failure of such cells to contribute to erythrocyte development; however, they can contribute to other hematopoietic lineages and tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Differentiation assays in vitro show proerythroblast arrest and apoptosis of these cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mouse embryos lacking GATA-1 die because of severe anemia secondary to arrested maturation of primitive erythroid cells, while GATA-1 loss in adult mice results in a condition resembling aplastic red blood cell crisis in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, a constitutive mutation in GATA-1 that interferes with the interaction with its essential cofactor FOG-1 (friend of GATA-1) is associated with familial dyserythropoietic anemia, defective megakaryocyte maturation, and macrothrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/55\">",
"     55",
"    </a>",
"    ]. Furthermore, infants with Down syndrome (DS) and transient myeloproliferative disorder (TMD) or acute megakaryoblastic leukemia (AMKL) have acquired mutations in the 5' region of GATA-1 that lead to a N-terminal truncated GATA-1 protein [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. These mutations are almost always present at birth, and therefore acquired in utero, and have also been noted in approximately 10 percent of neonates with DS and no evidence of TMD or AMKL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/58\">",
"     58",
"    </a>",
"    ]. It remains to be seen whether such infants will go on to develop AMKL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical features and diagnosis of Down syndrome\", section on 'Hematologic disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The EKLF transcription factor was found to be an activity bound to the CACCC site of the beta-globin promoter [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/59\">",
"     59",
"    </a>",
"    ]; it controls globin expression and some aspects of erythroid development.",
"   </p>",
"   <p>",
"    Whether precursor stem cells commit to erythroid or myeloid lineages may depend in part upon interactions between the GATA proteins (both GATA-1 and GATA-2) and PU.1 (Spi-1), a transcription factor essential for the development of myeloid cells. PU.1 appears to interact with a zinc finger domain of the GATA proteins via a helix-turn-helix wing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/60\">",
"     60",
"    </a>",
"    ]; this interaction appears to inhibit PU.1 activation of critical myeloid genes, as well as GATA transactivating functions, thereby suggesting that these effects have a role in the commitment of cells to either the erythroid or myeloid lineage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     GROWTH FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The regulation of the proliferation and maturation of erythroid progenitors depends upon interaction with a number of growth factors. The availability of pure recombinant growth factors, enrichment of target progenitor cells, use of defined \"serum-free\" culture conditions, and the targeted disruption of factors and their receptors have provided insights into the role of these factors during hematopoiesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythropoietin (EPO) is essential for the terminal maturation of erythroid cells. Its major effect appears to be at the level of the CFU-E during adult erythropoiesis; recombinant preparations are as effective as the natural hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CFU-E do not survive in vitro in the absence of EPO. Since the majority of CFU-E are cycling, their survival in the presence of EPO may be tightly linked to their proliferation and differentiation to mature erythrocytes.",
"   </p>",
"   <p>",
"    EPO also acts upon a subset of presumptive mature BFU-E, which requires EPO for survival and terminal maturation. A second subset of BFU-E, presumably less mature, survive EPO deprivation if other hematopoietic growth factors such as IL-3 or GM-CSF are present [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since EPO is crucial for the terminal differentiation of erythroid progenitors, mice with homozygous null mutations of the EPO or EPO receptor (EPOR) genes form BFU-E and CFU-E normally but these BFU-E and CFU-E fail to differentiate into mature erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/66\">",
"     66",
"    </a>",
"    ]. Both the",
"    <span class=\"nowrap\">",
"     EPO-/-",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     EPOR-/-",
"    </span>",
"    mutations are embryonically lethal due to failure of definitive (fetal liver) erythropoiesis. However, yolk sac erythropoiesis is only partially impaired, indicating the existence of a population of EPO-independent primary erythropoietic precursors.",
"   </p>",
"   <p>",
"    Insight into the molecular mechanism by which EPO prevents apoptosis in erythroid cells comes from studies of the signal transducer and activator of transcription 5 (STAT 5) proteins. STAT",
"    <span class=\"nowrap\">",
"     5A(-/-)",
"    </span>",
"    STAT",
"    <span class=\"nowrap\">",
"     5B(-/-)",
"    </span>",
"    mouse embryos are severely anemic during fetal development; the erythroid progenitors in fetal liver are reduced in number and show increased apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/67\">",
"     67",
"    </a>",
"    ]. This result was explained by the finding that STAT 5 mediates the early induction of the anti-apoptotic gene Bcl-X(L) through direct binding to its promoter. Although adult animals were thought to be hematologically normal, about half have chronic anemia with splenomegaly, due to an increase in early erythroid precursors; erythropoiesis is ineffective because of an increase in apoptosis in early normoblasts showing reduced levels of Bcl-X(L) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/68\">",
"     68",
"    </a>",
"    ]. In contrast, dominant gain-of-function mutations in the EPOR due to truncation of the cytoplasmic portion of the receptor lead to familial erythrocytosis (type 1) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/69\">",
"     69",
"    </a>",
"    ] because of elimination of the negative regulatory domain of the receptor that binds an inhibitory phosphatase SH-PTP-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stem Cell Factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although Stem Cell Factor (SCF) alone has no colony-forming ability, it has marked synergistic effects on BFU-E cultured in the presence of EPO [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. SCF is crucial for the normal development of CFU-E, since mice that lack SCF (Steel mutants) or its receptor c-kit (White spotting or W mutants) are severely anemic and have a reduction in fetal liver CFU-E [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/75\">",
"     75",
"    </a>",
"    ]. Studies of cell lines that express both c-kit and EPOR (HCD57 cells) or are transduced with cDNAs for these two receptors (32D cells) demonstrate that SCF supports the proliferation of these cells only if the EPOR is also present [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro, SCF induces tyrosine phosphorylation of the EPOR and c-kit associates with the cytoplasmic domain of the tyrosine phosphorylated EPOR. Whether such an interaction between c-kit and the EPOR occurs during normal erythropoiesis is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     IL-3 and GM-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin 3 (IL-3) and GM-CSF receptors share a common beta chain. Both cytokines enhance erythropoietin-dependent in vitro erythropoiesis by primary hematopoietic progenitors and factor-dependent cells. The beta chain interacts functionally and physically with the EPOR, thereby providing an explanation for the synergistic effects of IL-3 and GM-CSF on EPO-driven erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Insulin and insulin-like growth factor I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors distinct from the classical colony-stimulating factors may positively regulate erythropoiesis, either directly or indirectly. Limiting dilution studies of highly purified CFU-E in serum-free culture show that insulin and insulin-like growth factor I act directly on these cells in the presence of EPO [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/78\">",
"     78",
"    </a>",
"    ]. By comparison, earlier murine studies of unfractionated cells found that CFU-E respond to IGF-I or insulin in the absence of EPO [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Activin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another factor that enhances both BFU-E and CFU-E colony formation is activin. This protein dimer, also known as follicle stimulating hormone-releasing protein, appears to have a lineage-specific effect on erythropoiesis that is indirect, since removal of monocytes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T lymphocytes abrogates its activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/80\">",
"     80",
"    </a>",
"    ]. Activin is the factor produced by vegetal cells during blastogenesis that induces animal ectodermal cells to form primary mesoderm [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hepatocyte growth factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatocyte growth factor (HGF) is another factor that has synergistic effects on CFU-GEMM and BFU-E in EPO-containing cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/82\">",
"     82",
"    </a>",
"    ]. Its physiologic role in erythropoiesis remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1280406\">",
"    <span class=\"h1\">",
"     MicroRNAs",
"    </span>",
"    &nbsp;&mdash;&nbsp;MicroRNAs (miRNAs) are 18 to 25 nucleotide non-protein encoding RNAs that play important roles in the regulation of post transcriptional gene expression. After RNA polymerase II mediated transcription, the primary hairpin transcript (pri-miRNA) is processed in the nucleus by Drosha and DGCR8 into pre-miRNA, which is exported into the cytoplasm. Pre-miRNA is further processed by",
"    <span class=\"nowrap\">",
"     Dicer/TAR",
"    </span>",
"    RNA binding protein, and one strand of the duplex is degraded while the other is incorporated into the RNA-induced silencing complex (RISC) that contains the Argonaute proteins. The miRNA strand guides RISC typically to complementary sequences in the 3&rsquo; untranslated region of target mRNA by Watson Crick base-pairing, and leads to either mRNA degradation or translational repression.",
"   </p>",
"   <p>",
"    There is now strong evidence that miRNAs are important for erythropoiesis. Many miRNAs are expressed in developing erythroid cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]; most appear to decline in expression level as precursors mature, suggesting that they might regulate the timing of genes important for the synthesis of late erythroid proteins. For example, miR-191 is downregulated, and overexpression in mouse fetal liver cells results in a block in enucleation, a late event in erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/85\">",
"     85",
"    </a>",
"    ]. As expected, two miR-191 target genes identified in this study, Riok3 and Mxi1, are upregulated during erythropoiesis. Knockdown of these genes led to a similar block in enucleation. Other miRNAs that decrease in expression during differentiation act an earlier stage of erythropoiesis. Both miR-221 and miR-222 are encoded on a common pre-miRNA; they target and repress KIT expression, so overexpression impairs the proliferation of erythroid precursors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/86\">",
"     86",
"    </a>",
"    ]. miR-223 targets LMO2 mRNA (see above), and overexpression leads to a block in CD34 cell proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. miR-150 appears to regulate MYB levels critical for lineage commitment of bipotential myeloid erythroid progenitors (MEP). Overexpression of miR-150 leads to a decrease in MYB levels that then drives megakaryocyte at the expense of erythroid differentiation. Interestingly, thrombopoietin (TPO) induces miR-150 expression, suggesting another mechanism by which TPO induces megakaryocyte production [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other miRNAs, such as miR-144 and miR-451, increase in expression level during erythropoiesis; both are co-expressed in a bi-cistronic pri-miRNA that is activated by GATA-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/89\">",
"     89",
"    </a>",
"    ]. Enforced expression of these two miRs enhances erythropoiesis while depletion of miR-451 has the opposite effect [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/83,90\">",
"     83,90",
"    </a>",
"    ]. GATA-2 is a target of miR-451 in zebrafish [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/91\">",
"     91",
"    </a>",
"    ], and since down-regulation of GATA-2 is required for normal erythropoiesis, this might explain the effect of miR-451 depletion. Other experiments suggest that the",
"    <span class=\"nowrap\">",
"     miR-144/451",
"    </span>",
"    effect is more complex, and different mouse models show different phenotypes ranging from an erythroblast block [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/92\">",
"     92",
"    </a>",
"    ] to a hemolytic anemia with an increase in reticulocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/93\">",
"     93",
"    </a>",
"    ]. The differences in phenotype may lie in the degree of oxidative stress produced in these animals, as exposure to H",
"    <sub>",
"     2",
"    </sub>",
"    O",
"    <sub>",
"     2",
"    </sub>",
"    leads to increased accumulation of reactive oxygen species in",
"    <span class=\"nowrap\">",
"     miR144/451",
"     <sup>",
"      -/-",
"     </sup>",
"    </span>",
"    erythroid cells. These cells have a reduction in the accumulation of nuclear FoxO3, a transcription factor that is a master regulator of anti-oxidant responses. There is evidence that one of the major targets of miR-451 is 14-3-3zeta, a",
"    <span class=\"nowrap\">",
"     phospho-serine/threonine",
"    </span>",
"    binding protein that negatively regulates FoxO3 by localizing it to the cytoplasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     HYPOXIA AND EPO EXPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;EPO has long been recognized as the physiologic regulator of red cell production [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/94-97\">",
"     94-97",
"    </a>",
"    ]. It is produced in the kidney and the fetal liver in response to hypoxia or exposure to cobalt chloride.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hypoxia-inducible factor and the response to hypoxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specialized interstitial cells in the inner cortex and outer medulla of the kidney respond to hypoxia by producing and secreting EPO. Downstream events from the oxygen sensor involved in activation of EPO gene expression require stabilization and activation of specific transcription factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/98\">",
"     98",
"    </a>",
"    ]. One of these is the heterodimeric transcription factor complex hypoxia-inducible factor (HIF-1), comprising both HIF-1-alpha and HIF-1-beta subunits [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/98-101\">",
"     98-101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While HIF-1-beta is ubiquitously expressed independent of oxygen tension, HIF-1-alpha is only detectable under hypoxic conditions (",
"    <a class=\"graphic graphic_figure graphicRef53801 \" href=\"UTD.htm?3/26/3503\">",
"     figure 4",
"    </a>",
"    ). Above a critical oxygen concentration HIF-1-alpha is ubiquitinated and rapidly degraded in proteosomes. This oxygen sensor in mammalian cells appears to be a proline hydroxylase (prolyl hydroxylase domain proteins PHD1, PHD2, and PHD3) that adds a hydroxyl moiety in an oxygen- and iron-dependent manner to P-564 of HIF-1-alpha; P-564 lies within a highly conserved region of HIF-1-alpha that binds the von Hippel-Lindau (VHL) protein. When P-564 hydroxylated HIF-1-alpha binds VHL, an ubiquitin E3 ligase complex is activated, leading to ubiquitination and subsequent destruction of HIF-1-alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/98,102-108\">",
"     98,102-108",
"    </a>",
"    ]. A second related protein, HIF-2-alpha, is also subject to oxygen dependent prolyl hydroxylation, and also dimerizes with HIF-1-beta to form HIF-2. HIF-1-alpha is expressed in all nucleated cells, while HIF-1-beta expression is restricted to vascular endothelial cells, renal interstitial cells, hepatocytes, cardiomyocytes and astrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A homozygous R200W mutation of the VHL gene leads to reduction in the interaction of VHL with hydroxylated HIF, accumulation of HIF, and excessive erythrocyte production in Chuvash polycythemia (familial erythrocytosis, type 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/109\">",
"     109",
"    </a>",
"    ]. A different set of dominantly inherited mutations is found in the von Hippel-Lindau syndrome, with loss of the second normal allele in the tumors that characterize this disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=see_link&amp;anchor=H10#H10\">",
"     \"Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera\", section on 'von Hippel Lindau gene mutation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=see_link&amp;anchor=H24#H24\">",
"     \"Diagnostic approach to the patient with polycythemia\", section on 'Tumor polycythemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=see_link\">",
"     \"Molecular biology and pathogenesis of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An autosomal dominant form of erythrocytosis occurs with mutations the EGLN1 gene that encodes PHD2 (familial erythrocytosis, type 3) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/110\">",
"     110",
"    </a>",
"    ]. These mutations may have dominant negative effects because",
"    <span class=\"nowrap\">",
"     PHD2",
"     <sup>",
"      +/-",
"     </sup>",
"    </span>",
"    heterozygous mice do not have erythrocytosis.",
"   </p>",
"   <p>",
"    Additionally, mutations in the EPAS1 gene that encodes HIF-2-alpha can also cause familial erythrocytosis (type 4) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/111\">",
"     111",
"    </a>",
"    ]. These mutations interfere with the interaction of HIF-2-alpha with PHD2, thereby reducing hydroxylation. Mice with targeted disruption of the EPAS1 gene are anemic, emphasizing the importance of HIF-2-alpha in EPO regulation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIF-1 activity is induced in a variety of cell types in response to hypoxia or cobalt [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/113\">",
"     113",
"    </a>",
"    ]; this finding suggests that, while HIF-1 is important in the activation of EPO expression, it also plays a role in the activation of other hypoxia-inducible genes, including angiogenesis and glycolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/99,114-116\">",
"     99,114-116",
"    </a>",
"    ], and may play a role in the regulation of more than 2 percent of all human genes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/117\">",
"     117",
"    </a>",
"    ]. HIF-1-alpha may also bind to and negatively regulate the hepcidin promoter, leading to decreased levels of hepcidin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/118\">",
"     118",
"    </a>",
"    ]. Through coordinate downregulation of hepcidin and upregulation of ferroportin and erythropoietin, the VHL pathway effectively mobilizes iron in support of increased red cell production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link&amp;anchor=H16#H16\">",
"     \"Regulation of iron balance\", section on 'Hepcidin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The activity of HIF-1 is essential for survival. Mice that lack HIF-1 die at midgestation, while heterozygotes, although developmentally normal and similar to normal mice in normoxic conditions, fail to respond adequately to chronic hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of angiogenesis inhibitors\", section on 'Effect of hypoxia and cytokines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIF-1 binds to an",
"    <strong>",
"     enhancer",
"    </strong>",
"    sequence located approximately 130 base pairs downstream from the poly-A addition signal of the EPO gene. This enhancer segment renders other promoter-reporter gene constructs hypoxia-responsive with typical inductions in the range of 4 to 15 fold; this degree of stimulation is significantly less than the 50 to 100 fold induction observed with the chromosomal EPO gene in Hep 3B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have identified a 53 base pair sequence in the EPO promoter with important regulatory characteristics. This sequence confers oxygen-sensitivity (6 to 10-fold inducibility) to a luciferase reporter gene [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/121\">",
"     121",
"    </a>",
"    ]. The combination of both the enhancer and promoter sequences results in cooperative (50-fold) inducibility of transcription of EPO in response to hypoxia, enhancements approaching that observed in vivo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Hepatocyte nuclear factor 4 and p300",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because both promoter and enhancer sequence elements include the consensus hexanucleotide nuclear hormone receptor response elements, various orphan members of this gene family have been examined for binding to the EPO promoter and enhancer and for their presence in transcription complexes isolated from Hep 3B nuclear extracts. One of these, hepatocyte nuclear factor 4 (HNF-4) is present in these extracts and plays a critical role in hypoxia-induced activation of EPO gene expression in Hep 3B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/122\">",
"     122",
"    </a>",
"    ]. HIF-1a and -1b also bind to a large protein p300 (homologous to the cyclic AMP response element (CREB) binding protein [CBP]) that acts as a general transcriptional activator for a number of genes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect is that HIF-1a, which accumulates in response to hypoxia, combines with its partner HIF-1b and with HNF-4 and p300 to activate EPO transcription. The role of HIF-2 in this process is under active investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/124\">",
"     124",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=see_link&amp;anchor=H12#H12\">",
"     \"Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera\", section on 'Hypoxia inducible factor 2 gene mutation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     STRESS AND ERYTHROPOIESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level of oxyhemoglobin and the rate of delivery of oxygen to the tissues are the fundamental regulators of erythropoiesis (",
"    <a class=\"graphic graphic_figure graphicRef53916 \" href=\"UTD.htm?34/53/35677\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/125\">",
"     125",
"    </a>",
"    ]. In species that package hemoglobin in erythrocytes, erythropoietin mediates the response to oxygen demand; it performs this function by interacting with specific receptors that are found on the surface of committed erythroid progenitor cells and erythroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/126-130\">",
"     126-130",
"    </a>",
"    ]. As noted above, hypoxia induces a transcriptional increase in expression of the EPO gene via HIF-1a and HIF-1b [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/99,100\">",
"     99,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vivo, BFU-E do not give rise to erythroblasts except under conditions of",
"    <strong>",
"     extreme",
"    </strong>",
"    anemic stress. Instead, they mature to single CFU-E; in vivo, CFU-E divide and, under the influence of lower concentrations of erythropoietin, form single, relatively small colonies of proerythroblasts at about one week in vitro.",
"   </p>",
"   <p>",
"    The bone marrow of an adult mouse contains about 500 CFU-E per 10",
"    <sup>",
"     5",
"    </sup>",
"    nucleated cells. In response to anemic stress, as in hemorrhage or hemolysis, almost the entire burden of accelerated reticulocyte production is borne by the rapid erythropoietin-dependent influx from the progenitor compartment into the proerythroblast pool, resulting in an expanded proerythroblast pool [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anemic stress produces little or no increase in the mitotic rate of recognizable erythroid precursors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/131\">",
"     131",
"    </a>",
"    ]. Instead, the following changes are seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The late BFU-E and CFU-E proliferate (because of EPO binding to its receptors) and differentiate to proerythroblasts and beyond. In normal murine marrow, the CFU-E frequency increases from about 500 per 10",
"      <sup>",
"       5",
"      </sup>",
"      nucleated cells to 1000 to 2000 CFU-E per 10",
"      <sup>",
"       5",
"      </sup>",
"      nucleated cells following experimental hemorrhage or hemolysis. By comparison, hypertransfused mice show an 80 to 90 percent reduction in number of CFU-E.",
"     </li>",
"     <li>",
"      The orderly progression from immature BFU-E through CFU-E to proerythroblast is interrupted. High erythropoietin levels permit or induce differentiation of immature progenitors to proerythroblasts. In the rhesus monkey, this premature terminal differentiation may account for the marked increase in fetal hemoglobin content and F cells observed during stress erythropoiesis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/132\">",
"       132",
"      </a>",
"      ]. In contrast, progenitors in humans have a lesser ability to generate erythroblasts capable of synthesizing large quantities of fetal hemoglobin [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/133\">",
"       133",
"      </a>",
"      ]. As a result, the accumulation of F cells in peripheral blood in response to anemia is relatively small [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/134\">",
"       134",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such red cells are usually macrocytic and carry the i antigen. However, these two characteristics may relate to a short transit time through the marrow in response to erythropoietin rather than an intrinsic characteristic of fetal hemoglobin-containing cells themselves.",
"   </p>",
"   <p>",
"    F cells are also present in very small numbers in the blood of normal individuals, but these cells are not macrocytic and do not bear i antigen. F cell progenitors can be easily detected in the bone marrow of patients with various dyspoieses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/135,136\">",
"     135,136",
"    </a>",
"    ] and even in normal marrows [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     NEGATIVE REGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal humans, subsets of lymphocytes with a suppressor phenotype may inhibit erythroid activity in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/138-140\">",
"     138-140",
"    </a>",
"    ]. This finding is consistent with reports of patients in whom anemia or granulocytopenia is associated with an expansion of certain T lymphocyte populations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/141-145\">",
"     141-145",
"    </a>",
"    ]. In the rare disorder named T lymphocytosis with cytopenia, in vitro suppression of erythropoiesis correlates with expansion of a T lymphocyte population; these cells may be the counterpart of the hematopoietic suppressor cells isolated from normal blood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/146\">",
"     146",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The phenotype of this T suppressor cell has been described in detail [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/146,147\">",
"     146,147",
"    </a>",
"    ]. The cell is a large granular lymphocyte that is both E rosette-positive and CD8 (classic suppressor phenotype)-positive. Such suppressor T cells may also be involved in some cases of aplastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/148,149\">",
"     148,149",
"    </a>",
"    ], neutropenia without an underlying immunologic disorder, or overt T cell proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/150\">",
"     150",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unknown exactly how these suppressor T cells interact with hematopoietic progenitors, and what surface antigens are \"seen\" by the suppressor cells. Suppression of erythroid colony expression in vitro may be regulated by T cells in a genetically restricted fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/147,151\">",
"     147,151",
"    </a>",
"    ]. Cell-cell interactions in immunologic systems have been well characterized with regard to surface determinants that permit cellular recognition. The observation that hematopoietic progenitors have a unique distribution of class II histocompatibility antigens on their cell surface suggests a role for these antigens in the cell-cell interactions that regulate hematopoietic differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/152-154\">",
"     152-154",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    T cells may also inhibit erythropoiesis via the production of inhibitory cytokines. Some lymphokines may inhibit erythropoiesis in vitro via a complex lymphokine cascade:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation of T cells by the T cell antigen receptor CD3 results in cell surface expression of the interleukin (IL)-2 receptor alpha chain and the acquisition of IL-2 responsiveness [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/155\">",
"       155",
"      </a>",
"      ]. IL-2 inhibits BFU-E in the presence of these IL-2 R positive cells, possibly by inducing their release of interferon (IFN)-gamma.",
"     </li>",
"     <li>",
"      CD2 can serve as an alternative pathway of T cell activation, via binding to its ligand, LFA-3, on antigen-presenting cells. Blockade of CD2 with monoclonal antibody leads to abrogation of",
"      <span class=\"nowrap\">",
"       IL-2/IFN-gamma",
"      </span>",
"      mediated BFU-E suppression [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/156\">",
"       156",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tumor necrosis factor also suppresses erythropoiesis in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/157,158\">",
"       157,158",
"      </a>",
"      ]. Evidence for this is derived from studies in Friend murine leukemia virus infected animals in which the injection of peritoneal macrophages results in rapid but transient resolution of the massive erythroid hyperplasia associated with this disease. This effect may be due to elaboration by macrophages of IL-1-alpha, which acts via induction of tumor necrosis factor. Macrophage-mediated inhibition of erythropoiesis is reversed by EPO [",
"      <a class=\"abstract\" href=\"UTD.htm?20/10/20650/abstract/159\">",
"       159",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20133062\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythropoiesis begins with the differentiation of a small pool of pluripotent stem cells into primitive erythroid progenitors. These develop into erythroid precursors, culminating in the emergence of mature erythrocytes. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Erythroid progenitor cells'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Precursors and mature cells'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The erythroid maturation process is driven by transcription factors as well as hematopoietic growth factors and their receptors (",
"      <a class=\"graphic graphic_figure graphicRef70092 \" href=\"UTD.htm?12/31/12799\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef55127 \" href=\"UTD.htm?2/44/2752\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Transcription factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Growth factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Erythropoietin (EPO) is the physiologic regulator of red cell production, produced in the kidney and the fetal liver in response to hypoxia due to anemia or other causes (",
"      <a class=\"graphic graphic_figure graphicRef53801 \" href=\"UTD.htm?3/26/3503\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef53916 \" href=\"UTD.htm?34/53/35677\">",
"       figure 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Erythropoietin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Hypoxia and EPO expression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/1\">",
"      Suda T, Suda J, Ogawa M. Disparate differentiation in mouse hemopoietic colonies derived from paired progenitors. Proc Natl Acad Sci U S A 1984; 81:2520.",
"     </a>",
"    </li>",
"    <li>",
"     Axelrad AA, McLeod DL, et al. Properties of cells that produce erythrocytic colonies in vitro. In: Hematopoiesis in Culture, Robinson, WA (Eds), National Institutes of Health, Washington 1974. p.226.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/3\">",
"      Emerson SG, Sieff CA, Wang EA, et al. Purification of fetal hematopoietic progenitors and demonstration of recombinant multipotential colony-stimulating activity. J Clin Invest 1985; 76:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/4\">",
"      Dicke KA, van Noord MJ, Maat B, et al. Identification of cells in primate bone marrow resembling the hemopoietic stem cell in the mouse. Blood 1973; 42:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/5\">",
"      Rosse C. Small lymphocyte and transitional cell populations of the bone marrow; their role in the mediation of immune and hemopoietic progenitor cell functions. Int Rev Cytol 1976; 45:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/6\">",
"      Finch CA, Deubelbeiss K, Cook JD, et al. Ferrokinetics in man. Medicine (Baltimore) 1970; 49:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/7\">",
"      Lord BI. Kinetics of the recognizable erythrocyte precursor cells. Clin Haematol 1979; 8:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/8\">",
"      Hillman RS, Giblett ER. Red cell membrane alteration associated with \"marrow stress\". J Clin Invest 1965; 44:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/9\">",
"      Nathan DG. Rubbish in the red cell. N Engl J Med 1969; 281:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/10\">",
"      Etlinger JD, Goldberg AL. Control of protein degradation in reticulocytes and reticulocyte extracts by hemin. J Biol Chem 1980; 255:4563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/11\">",
"      M&uuml;ller-Sieburg CE, Deryugina E. The stromal cells' guide to the stem cell universe. Stem Cells 1995; 13:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/12\">",
"      Clark BR, Keating A. Biology of bone marrow stroma. Ann N Y Acad Sci 1995; 770:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/13\">",
"      Patel VP, Lodish HF. Loss of adhesion of murine erythroleukemia cells to fibronectin during erythroid differentiation. Science 1984; 224:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/14\">",
"      Patel VP, Lodish HF. The fibronectin receptor on mammalian erythroid precursor cells: characterization and developmental regulation. J Cell Biol 1986; 102:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/15\">",
"      Tsai S, Patel V, Beaumont E, et al. Differential binding of erythroid and myeloid progenitors to fibroblasts and fibronectin. Blood 1987; 69:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/16\">",
"      Hamamura K, Matsuda H, Takeuchi Y, et al. A critical role of VLA-4 in erythropoiesis in vivo. Blood 1996; 87:2513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/17\">",
"      Sadahira Y, Yoshino T, Monobe Y. Very late activation antigen 4-vascular cell adhesion molecule 1 interaction is involved in the formation of erythroblastic islands. J Exp Med 1995; 181:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/18\">",
"      Yanai N, Sekine C, Yagita H, Obinata M. Roles for integrin very late activation antigen-4 in stroma-dependent erythropoiesis. Blood 1994; 83:2844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/19\">",
"      Rhodes MM, Kopsombut P, Bondurant MC, et al. Adherence to macrophages in erythroblastic islands enhances erythroblast proliferation and increases erythrocyte production by a different mechanism than erythropoietin. Blood 2008; 111:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/20\">",
"      Chow A, Huggins M, Ahmed J, et al. CD169+ macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat Med 2012; 19:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/21\">",
"      Chasis JA, Mohandas N. Erythroblastic islands: niches for erythropoiesis. Blood 2008; 112:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/22\">",
"      Kawane K, Fukuyama H, Kondoh G, et al. Requirement of DNase II for definitive erythropoiesis in the mouse fetal liver. Science 2001; 292:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/23\">",
"      Shivdasani RA, Orkin SH. The transcriptional control of hematopoiesis. Blood 1996; 87:4025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/24\">",
"      Begley CG, Aplan PD, Davey MP, et al. Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. Proc Natl Acad Sci U S A 1989; 86:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/25\">",
"      Finger LR, Kagan J, Christopher G, et al. Involvement of the TCL5 gene on human chromosome 1 in T-cell leukemia and melanoma. Proc Natl Acad Sci U S A 1989; 86:5039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/26\">",
"      Begley CG, Aplan PD, Denning SM, et al. The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. Proc Natl Acad Sci U S A 1989; 86:10128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/27\">",
"      Mouthon MA, Bernard O, Mitjavila MT, et al. Expression of tal-1 and GATA-binding proteins during human hematopoiesis. Blood 1993; 81:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/28\">",
"      Shivdasani RA, Mayer EL, Orkin SH. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature 1995; 373:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/29\">",
"      Robb L, Lyons I, Li R, et al. Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene. Proc Natl Acad Sci U S A 1995; 92:7075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/30\">",
"      Visvader JE, Fujiwara Y, Orkin SH. Unsuspected role for the T-cell leukemia protein SCL/tal-1 in vascular development. Genes Dev 1998; 12:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/31\">",
"      Mikkola HK, Klintman J, Yang H, et al. Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. Nature 2003; 421:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/32\">",
"      Aplan PD, Nakahara K, Orkin SH, Kirsch IR. The SCL gene product: a positive regulator of erythroid differentiation. EMBO J 1992; 11:4073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/33\">",
"      Hoang T, Paradis E, Brady G, et al. Opposing effects of the basic helix-loop-helix transcription factor SCL on erythroid and monocytic differentiation. Blood 1996; 87:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/34\">",
"      Boehm T, Foroni L, Kaneko Y, et al. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci U S A 1991; 88:4367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/35\">",
"      Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/36\">",
"      Warren AJ, Colledge WH, Carlton MB, et al. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell 1994; 78:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/37\">",
"      Valge-Archer VE, Osada H, Warren AJ, et al. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells. Proc Natl Acad Sci U S A 1994; 91:8617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/38\">",
"      Wadman I, Li J, Bash RO, et al. Specific in vivo association between the bHLH and LIM proteins implicated in human T cell leukemia. EMBO J 1994; 13:4831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/39\">",
"      Dorfman DM, Wilson DB, Bruns GA, Orkin SH. Human transcription factor GATA-2. Evidence for regulation of preproendothelin-1 gene expression in endothelial cells. J Biol Chem 1992; 267:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/40\">",
"      Leonard M, Brice M, Engel JD, Papayannopoulou T. Dynamics of GATA transcription factor expression during erythroid differentiation. Blood 1993; 82:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/41\">",
"      Visvader J, Adams JM. Megakaryocytic differentiation induced in 416B myeloid cells by GATA-2 and GATA-3 transgenes or 5-azacytidine is tightly coupled to GATA-1 expression. Blood 1993; 82:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/42\">",
"      Briegel K, Lim KC, Plank C, et al. Ectopic expression of a conditional GATA-2/estrogen receptor chimera arrests erythroid differentiation in a hormone-dependent manner. Genes Dev 1993; 7:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/43\">",
"      Tsai FY, Keller G, Kuo FC, et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 1994; 371:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/44\">",
"      Fujimaki S, Harigae H, Sugawara T, et al. Decreased expression of transcription factor GATA-2 in haematopoietic stem cells in patients with aplastic anaemia. Br J Haematol 2001; 113:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/45\">",
"      Martin DI, Zon LI, Mutter G, Orkin SH. Expression of an erythroid transcription factor in megakaryocytic and mast cell lineages. Nature 1990; 344:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/46\">",
"      Romeo PH, Prandini MH, Joulin V, et al. Megakaryocytic and erythrocytic lineages share specific transcription factors. Nature 1990; 344:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/47\">",
"      Zon LI, Yamaguchi Y, Yee K, et al. Expression of mRNA for the GATA-binding proteins in human eosinophils and basophils: potential role in gene transcription. Blood 1993; 81:3234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/48\">",
"      Zheng J, Kitajima K, Sakai E, et al. Differential effects of GATA-1 on proliferation and differentiation of erythroid lineage cells. Blood 2006; 107:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/49\">",
"      Pevny L, Simon MC, Robertson E, et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature 1991; 349:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/50\">",
"      Simon MC, Pevny L, Wiles MV, et al. Rescue of erythroid development in gene targeted GATA-1- mouse embryonic stem cells. Nat Genet 1992; 1:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/51\">",
"      Weiss MJ, Keller G, Orkin SH. Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells. Genes Dev 1994; 8:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/52\">",
"      Pevny L, Lin CS, D'Agati V, et al. Development of hematopoietic cells lacking transcription factor GATA-1. Development 1995; 121:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/53\">",
"      Weiss MJ, Orkin SH. Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis. Proc Natl Acad Sci U S A 1995; 92:9623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/54\">",
"      Guti&eacute;rrez L, Tsukamoto S, Suzuki M, et al. Ablation of Gata1 in adult mice results in aplastic crisis, revealing its essential role in steady-state and stress erythropoiesis. Blood 2008; 111:4375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/55\">",
"      Nichols KE, Crispino JD, Poncz M, et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet 2000; 24:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/56\">",
"      Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/57\">",
"      Hitzler JK, Cheung J, Li Y, et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 2003; 101:4301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/58\">",
"      Ahmed M, Sternberg A, Hall G, et al. Natural history of GATA1 mutations in Down syndrome. Blood 2004; 103:2480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/59\">",
"      Miller IJ, Bieker JJ. A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Kr&uuml;ppel family of nuclear proteins. Mol Cell Biol 1993; 13:2776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/60\">",
"      Zhang P, Behre G, Pan J, et al. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc Natl Acad Sci U S A 1999; 96:8705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/61\">",
"      Sieff CA, Emerson SG, Mufson A, et al. Dependence of highly enriched human bone marrow progenitors on hemopoietic growth factors and their response to recombinant erythropoietin. J Clin Invest 1986; 77:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/62\">",
"      Eaves CJ, Eaves AC. Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera. Blood 1978; 52:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/63\">",
"      Eaves AC, Eaves CJ. Erythropoiesis in culture. Clin Haematol 1984; 13:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/64\">",
"      Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006; 354:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/65\">",
"      Sieff CA, Ekern SC, Nathan DG, Anderson JW. Combinations of recombinant colony-stimulating factors are required for optimal hematopoietic differentiation in serum-deprived culture. Blood 1989; 73:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/66\">",
"      Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/67\">",
"      Socolovsky M, Fallon AE, Wang S, et al. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999; 98:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/68\">",
"      Socolovsky M, Nam H, Fleming MD, et al. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 2001; 98:3261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/69\">",
"      de la Chapelle A, Tr&auml;skelin AL, Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A 1993; 90:4495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/70\">",
"      Klingm&uuml;ller U, Lorenz U, Cantley LC, et al. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995; 80:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/71\">",
"      Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/72\">",
"      Abkowitz JL, Sabo KM, Nakamoto B, et al. Diamond-blackfan anemia: in vitro response of erythroid progenitors to the ligand for c-kit. Blood 1991; 78:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/73\">",
"      Bagnara GP, Zauli G, Vitale L, et al. In vitro growth and regulation of bone marrow enriched CD34+ hematopoietic progenitors in Diamond-Blackfan anemia. Blood 1991; 78:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/74\">",
"      Olivieri NF, Grunberger T, Ben-David Y, et al. Diamond-Blackfan anemia: heterogenous response of hematopoietic progenitor cells in vitro to the protein product of the steel locus. Blood 1991; 78:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/75\">",
"      Nocka K, Majumder S, Chabot B, et al. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice. Genes Dev 1989; 3:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/76\">",
"      Wu H, Klingm&uuml;ller U, Besmer P, Lodish HF. Interaction of the erythropoietin and stem-cell-factor receptors. Nature 1995; 377:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/77\">",
"      Jubinsky PT, Krijanovski OI, Nathan DG, et al. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood 1997; 90:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/78\">",
"      Sawada K, Krantz SB, Dessypris EN, et al. Human colony-forming units-erythroid do not require accessory cells, but do require direct interaction with insulin-like growth factor I and/or insulin for erythroid development. J Clin Invest 1989; 83:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/79\">",
"      Kurtz A, Jelkmann W, Bauer C. Insulin stimulates erythroid colony formation independently of erythropoietin. Br J Haematol 1983; 53:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/80\">",
"      Yu J, Shao L, Vaughan J, et al. Characterization of the potentiation effect of activin on human erythroid colony formation in vitro. Blood 1989; 73:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/81\">",
"      Smith JC, Price BM, Van Nimmen K, Huylebroeck D. Identification of a potent Xenopus mesoderm-inducing factor as a homologue of activin A. Nature 1990; 345:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/82\">",
"      Galimi F, Bagnara GP, Bonsi L, et al. Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors. J Cell Biol 1994; 127:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/83\">",
"      Zhan M, Miller CP, Papayannopoulou T, et al. MicroRNA expression dynamics during murine and human erythroid differentiation. Exp Hematol 2007; 35:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/84\">",
"      Zhao G, Yu D, Weiss MJ. MicroRNAs in erythropoiesis. Curr Opin Hematol 2010; 17:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/85\">",
"      Zhang L, Flygare J, Wong P, et al. miR-191 regulates mouse erythroblast enucleation by down-regulating Riok3 and Mxi1. Genes Dev 2011; 25:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/86\">",
"      Felli N, Fontana L, Pelosi E, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A 2005; 102:18081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/87\">",
"      Lu J, Guo S, Ebert BL, et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell 2008; 14:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/88\">",
"      Barroga CF, Pham H, Kaushansky K. Thrombopoietin regulates c-Myb expression by modulating micro RNA 150 expression. Exp Hematol 2008; 36:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/89\">",
"      Dore LC, Amigo JD, Dos Santos CO, et al. A GATA-1-regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci U S A 2008; 105:3333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/90\">",
"      Papapetrou EP, Korkola JE, Sadelain M. A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells. Stem Cells 2010; 28:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/91\">",
"      Pase L, Layton JE, Kloosterman WP, et al. miR-451 regulates zebrafish erythroid maturation in vivo via its target gata2. Blood 2009; 113:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/92\">",
"      Patrick DM, Zhang CC, Tao Y, et al. Defective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3zeta. Genes Dev 2010; 24:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/93\">",
"      Yu D, dos Santos CO, Zhao G, et al. miR-451 protects against erythroid oxidant stress by repressing 14-3-3zeta. Genes Dev 2010; 24:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/94\">",
"      Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/95\">",
"      Blanchard KL, Fandrey J, Goldberg MA, Bunn HF. Regulation of the erythropoietin gene. Stem Cells 1993; 11 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/96\">",
"      Porter DL, Goldberg MA. Regulation of erythropoietin production. Exp Hematol 1993; 21:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/97\">",
"      Bunn HF, Gu J, Huang LE, et al. Erythropoietin: a model system for studying oxygen-dependent gene regulation. J Exp Biol 1998; 201:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/98\">",
"      Semenza GL. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 2009; 114:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/99\">",
"      Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92:5510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/100\">",
"      Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/101\">",
"      Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med 2011; 365:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/102\">",
"      Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998; 95:7987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/103\">",
"      Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000; 275:25733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/104\">",
"      Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/105\">",
"      Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001; 107:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/106\">",
"      Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/107\">",
"      Zhu H, Bunn HF. Signal transduction. How do cells sense oxygen? Science 2001; 292:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/108\">",
"      Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/109\">",
"      Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002; 32:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/110\">",
"      Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A 2006; 103:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/111\">",
"      Percy MJ, Furlow PW, Lucas GS, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 2008; 358:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/112\">",
"      Scortegagna M, Ding K, Zhang Q, et al. HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 2005; 105:3133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/113\">",
"      Weidemann A, Kerdiles YM, Knaup KX, et al. The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice. J Clin Invest 2009; 119:3373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/114\">",
"      Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994; 269:23757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/115\">",
"      Wykoff CC, Sotiriou C, Cockman ME, et al. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer 2004; 90:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/116\">",
"      Rathmell WK, Simon MC. VHL: oxygen sensing and vasculogenesis. J Thromb Haemost 2005; 3:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/117\">",
"      Manalo DJ, Rowan A, Lavoie T, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005; 105:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/118\">",
"      Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/119\">",
"      Yu AY, Shimoda LA, Iyer NV, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest 1999; 103:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/120\">",
"      Semenza GL, Koury ST, Nejfelt MK, et al. Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc Natl Acad Sci U S A 1991; 88:8725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/121\">",
"      Blanchard KL, Acquaviva AM, Galson DL, Bunn HF. Hypoxic induction of the human erythropoietin gene: cooperation between the promoter and enhancer, each of which contains steroid receptor response elements. Mol Cell Biol 1992; 12:5373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/122\">",
"      Galson DL, Tsuchiya T, Tendler DS, et al. The orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator for tissue-specific and hypoxia-specific erythropoietin gene expression and is antagonized by EAR3/COUP-TF1. Mol Cell Biol 1995; 15:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/123\">",
"      Arany Z, Huang LE, Eckner R, et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci U S A 1996; 93:12969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/124\">",
"      Frede S, Freitag P, Geuting L, et al. Oxygen-regulated expression of the erythropoietin gene in the human renal cell line REPC. Blood 2011; 117:4905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/125\">",
"      GRANT WC, ROOT WS. Fundamental stimulus for erythropoiesis. Physiol Rev 1952; 32:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/126\">",
"      D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell 1989; 57:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/127\">",
"      Krantz SB, Goldwasser E. Specific binding of erythropoietin to spleen cells infected with the anemia strain of Friend virus. Proc Natl Acad Sci U S A 1984; 81:7574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/128\">",
"      Sawyer ST, Krantz SB, Sawada K. Receptors for erythropoietin in mouse and human erythroid cells and placenta. Blood 1989; 74:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/129\">",
"      Sawada K, Krantz SB, Sawyer ST, Civin CI. Quantitation of specific binding of erythropoietin to human erythroid colony-forming cells. J Cell Physiol 1988; 137:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/130\">",
"      Akahane K, Tojo A, Fukamachi H, et al. Binding of iodinated erythropoietin to rat bone marrow cells under normal and anemic conditions. Exp Hematol 1989; 17:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/131\">",
"      ALPEN EL, CRANMORE D. Cellular kinetics and iron utilization in bone marrow as observed by Fe59 radioautography. Ann N Y Acad Sci 1959; 77:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/132\">",
"      Macklis RM, Javid J, Lipton JM, et al. Synthesis of hemoglobin F in adult simian erythroid progenitor-derived colonies. J Clin Invest 1982; 70:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/133\">",
"      Friedman AD, Linch DC, Miller B, et al. Determination of the hemoglobin F program in human progenitor-derived erythroid cells. J Clin Invest 1985; 75:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/134\">",
"      Dover GJ, Boyer SH, Zinkham WH. Production of erythrocytes that contain fetal hemoglobin in anemia. Transient in vivo changes. J Clin Invest 1979; 63:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/135\">",
"      Kidoguchi K, Ogawa M, Karam JD, Martin AG. Augmentation of fetal hemoglobin (HbF) synthesis in culture by human erythropoietic precursors in the marrow and peripheral blood: studies in sickle cell anemia and nonhemoglobinopathic adults. Blood 1978; 52:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/136\">",
"      Clarke BJ, Nathan DG, Alter BP, et al. Hemoglobin synthesis in human BFU-E and CFU-E-derived erythroid colonies. Blood 1979; 54:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/137\">",
"      Papayannopoulou T, Brice M, Stamatoyannopoulos G. Hemoglobin F synthesis in vitro: evidence for control at the level of primitive erythroid stem cells. Proc Natl Acad Sci U S A 1977; 74:2923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/138\">",
"      Mangan KF, Chikkappa G, Bieler LZ, et al. Regulation of human blood erythroid burst-forming unit (BFU-E) proliferation by T-lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies. Blood 1982; 59:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/139\">",
"      Torok-Storb B, Martin PJ, Hansen JA. Regulation of in vitro erythropoiesis by normal T cells: evidence for two T-cell subsets with opposing function. Blood 1981; 58:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/140\">",
"      Lipton JM, Smith BR, et al. Suppression of in vitro erythropoiesis by a subset of large granular lymphocytes. Blood 1984; 64:337a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/141\">",
"      Hoffman R, Kopel S, Hsu SD, et al. T cell chronic lymphocytic leukemia: presence in bone marrow and peripheral blood of cells that suppress erythropoiesis in vitro. Blood 1978; 52:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/142\">",
"      Bagby GC Jr. T lymphocytes involved in inhibition of granulopoiesis in two neutropenic patients are of the cytotoxic/suppressor (T3+T8+) subset. J Clin Invest 1981; 68:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/143\">",
"      Abdou NI, NaPombejara C, Balentine L, Abdou NL. Suppressor cell-mediated neutropenia in Felty's syndrome. J Clin Invest 1978; 61:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/144\">",
"      Sugimoto M, Wakabayashi Y, Shiokawa Y, Takaku F. Effect of peripheral blood lymphocytes from systemic lupus erythematosus patients on human bone marrow granulocyte precursor cells (colony-forming units in culture). Stem Cells 1982; 2:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/145\">",
"      Bom-van Noorloos AA, Pegels HG, van Oers RH, et al. Proliferation of T gamma cells with killer-cell activity in two patients with neutropenia and recurrent infections. N Engl J Med 1980; 302:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/146\">",
"      Linch DC, Cawley JC, MacDonald SM, et al. Acquired pure red-cell aplasia associated with an increase of T cells bearing receptors for the Fc of IgG. Acta Haematol 1981; 65:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/147\">",
"      Lipton JM, Nadler LM, Canellos GP, et al. Evidence for genetic restriction in the suppression of erythropoiesis by a unique subset of T lymphocytes in man. J Clin Invest 1983; 72:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/148\">",
"      Torok-Storb BJ, Sieff C, Storb R, et al. In vitro tests for distinguishing possible immune-mediated aplastic anemia from transfusion-induced sensitization. Blood 1980; 55:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/149\">",
"      Bacigalupo A, Podest&agrave; M, Mingari MC, et al. Immune suppression of hematopoiesis in aplastic anemia: activity of T-gamma lymphocytes. J Immunol 1980; 125:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/150\">",
"      Smith BR, Lipton JM, et al. Multiparameter flow cytometric characterization of a unique T-lymphocyte subclass associated with granulocytopenia and pure red cell aplasia. Blood 1984; 64:343a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/151\">",
"      Torok-Storb B, Hansen JA. Modulation of in vitro BFU-E growth by normal Ia-positive T cells is restricted by HLA-DR. Nature 1982; 298:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/152\">",
"      Falkenburg JH, Jansen J, van der Vaart-Duinkerken N, et al. Polymorphic and monomorphic HLA-DR determinants on human hematopoietic progenitor cells. Blood 1984; 63:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/153\">",
"      Sieff C, Bicknell D, Caine G, et al. Changes in cell surface antigen expression during hemopoietic differentiation. Blood 1982; 60:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/154\">",
"      Sparrow RL, Williams N. The pattern of HLA-DR and HLA-DQ antigen expression on clonable subpopulations of human myeloid progenitor cells. Blood 1986; 67:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/155\">",
"      Burdach SE, Levitt LJ. Receptor-specific inhibition of bone marrow erythropoiesis by recombinant DNA-derived interleukin-2. Blood 1987; 69:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/156\">",
"      Burdach S, Shatsky M, Wagenhorst B, Levitt L. The T-cell CD2 determinant mediates inhibition of erythropoiesis by the lymphokine cascade. Blood 1988; 72:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/157\">",
"      Roodman GD, Bird A, Hutzler D, Montgomery W. Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells. Exp Hematol 1987; 15:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/158\">",
"      Broxmeyer HE, Williams DE, Lu L, et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol 1986; 136:4487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/10/20650/abstract/159\">",
"      Furmanski P, Johnson CS. Macrophage control of normal and leukemic erythropoiesis: identification of the macrophage-derived erythroid suppressing activity as interleukin-1 and the mediator of its in vivo action as tumor necrosis factor. Blood 1990; 75:2328.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7161 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_10_20650=[""].join("\n");
var outline_f20_10_20650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20133062\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ERYTHROID PROGENITOR CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRECURSORS AND MATURE CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      STROMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TRANSCRIPTION FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tal-1/SCL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Rbtn2/LMO2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GATA-2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GATA-1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      GROWTH FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stem Cell Factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      IL-3 and GM-CSF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Insulin and insulin-like growth factor I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Activin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hepatocyte growth factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1280406\">",
"      MicroRNAs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HYPOXIA AND EPO EXPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hypoxia-inducible factor and the response to hypoxia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Hepatocyte nuclear factor 4 and p300",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      STRESS AND ERYTHROPOIESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NEGATIVE REGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20133062\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7161\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7161|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/31/12799\" title=\"figure 1\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/44/2752\" title=\"figure 2\">",
"      Erythroid maturation sequence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/34/33325\" title=\"figure 3\">",
"      Reticulocyte shift",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/26/3503\" title=\"figure 4\">",
"      Oxygen sensor model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/53/35677\" title=\"figure 5\">",
"      Serum EPO and anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7161|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/7/40050\" title=\"picture 1\">",
"      Erythroid precursors marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/22/40294\" title=\"picture 2A\">",
"      Basophilic stippling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/28/26054\" title=\"picture 2B\">",
"      Heinz body hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/45/39638\" title=\"picture 2C\">",
"      Howell-Jolly bodies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=related_link\">",
"      Diagnostic approach to the patient with polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=related_link\">",
"      Molecular biology and pathogenesis of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=related_link\">",
"      Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36326?source=related_link\">",
"      Red blood cell survival: Normal values and measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_10_20651="Nongastrointestinal sx celiac";
var content_f20_10_20651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nongastrointestinal nonmalignant symptoms of celiac disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Infertility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Vitamin D and calcium deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Osteomalacia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Osteoporosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Neurologic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Depression - 10.6 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Epilepsy - 3.5 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Migraine headaches - 3.2 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anxiety - 2.6 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Suicidal tendency - 2.1 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Carpal tunnel syndrome - 1.8 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Myopathy - 1.5 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Holmes JKT. Non-malignant complications of coeliac disease. Acta Paediatr 1996; 412(Suppl):68.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_10_20651=[""].join("\n");
var outline_f20_10_20651=null;
var title_f20_10_20652="Platelet aggregation";
var content_f20_10_20652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patterns of platelet aggregation in selected disorders of platelet function",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Disorder",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"4\">",
"       Aggregation response",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Other features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Primary ADP",
"      </td>",
"      <td class=\"subtitle2\">",
"       Secondary ADP",
"      </td>",
"      <td class=\"subtitle2\">",
"       Collagen",
"      </td>",
"      <td class=\"subtitle2\">",
"       Ristocetin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       vWD",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       Highly variable",
"      </td>",
"      <td>",
"       Platelet morphology normal; vWD panel is usually abnormal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bernard-Soulier syndrome",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       Giant platelets, thrombocytopenia-vWD panel normal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Glanzmann's thrombasthenia",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       +++",
"      </td>",
"      <td>",
"       Normal platelet morphology",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Storage pool disease",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       0 to ++",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       Platelet morphology normal (except in gray platelet subgroup); electron microscopy abnormal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Secretion defect",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       0 to ++",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       ++++",
"      </td>",
"      <td>",
"       Normal morphology by light and electron microscopy",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Acquired (eg, aspirin) or inherited COX-1 defects can be tested using arachidonic acid as the agonist. Results will show absent aggregation response to arachidonic acid as well as reduced secondary aggregation to ADP. Thromboxane receptor defects can be tested for using U-46619 in conjunction with this.",
"    <div class=\"footnotes\">",
"     ++++: normal response; +++: slightly reduced response; ++: reduced response; +: markedly reduced response; 0: no response; ADP: adenosine diphosphate; vWD: von Willebrand disease.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Rodgers, GM. Qualitative platelet disorders and von Willebrand's disease. In: Practical Diagnosis of Hematologic Disorders, 2nd ed., Kjeldsberg, C, Foucar, K, McKenna, RW, et al. (Eds), ASCP Press, Chicago 1995. Copyright &copy; 1995-2010 American Society for Clinical Pathology and ASCP Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_10_20652=[""].join("\n");
var outline_f20_10_20652=null;
var title_f20_10_20653="Pediatric physical activity for CV health";
var content_f20_10_20653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Activity recommendations for cardiovascular health from the Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Activity&nbsp;recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        0-12 m",
"       </td>",
"       <td>",
"        Parents should create an environment promoting and modeling physical activity and limiting sedentary time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Supportive actions:",
"        </em>",
"        <br/>",
"        <ul>",
"         <li>",
"          Discourage TV viewing altogether",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        1-4 y",
"       </td>",
"       <td>",
"        Unlimited active playtime in safe, supportive environment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limit sedentary time, especially TV/video",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Supportive actions:",
"        </em>",
"        <ul>",
"         <li>",
"          For children &lt;2 years, discourage television viewing altogether",
"         </li>",
"         <li>",
"          Limit total media time to no more than 1 to 2 hours of quality programming per day",
"         </li>",
"         <li>",
"          No TV in child's bedroom",
"         </li>",
"         <li>",
"          Encourage family activity at least once per week",
"         </li>",
"         <li>",
"          Counsel routine activity for parents as role models for children",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        5-10 y",
"       </td>",
"       <td>",
"        Moderate to vigorous physical activity* every day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limit daily leisure screen time (TV/video/computer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Supportive actions:",
"        </em>",
"        <br/>",
"        <ul>",
"         <li>",
"          Prescribe moderate to vigorous activity* 1 h/d with vigorous intensity physical activity",
"          <sup>",
"           &Delta;",
"          </sup>",
"          on 3 d/wk",
"         </li>",
"         <li>",
"          Limit total media time to no more than 1 to 2 hours of quality programming per day",
"         </li>",
"         <li>",
"          No TV in child's bedroom",
"         </li>",
"         <li>",
"          Take activity and screen time history from child once a year",
"         </li>",
"         <li>",
"          Match physical activity recommendations with energy intake",
"         </li>",
"         <li>",
"          Recommend appropriate safety equipment relative to each sport",
"         </li>",
"         <li>",
"          Support recommendations for daily physical education in schools",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        11-17 y",
"       </td>",
"       <td>",
"        Moderate to vigorous physical activity* every day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limit leisure time TV/video/computer use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Supportive actions:",
"        </em>",
"        <br/>",
"        <ul>",
"         <li>",
"          Encourage adolescents to aim for 1 h/d of moderate to vigorous daily activity*, with vigorous intense physical activity",
"          <sup>",
"           &Delta;",
"          </sup>",
"          on 3 d/wk",
"         </li>",
"         <li>",
"          Encourage no TV in bedroom",
"         </li>",
"         <li>",
"          Limit total media time to no more than 1 to 2 hours of quality programming per day",
"         </li>",
"         <li>",
"          Match activity recommendations with energy intake",
"         </li>",
"         <li>",
"          Take activity and screen time history from adolescent at health supervision visits",
"         </li>",
"         <li>",
"          Encourage involvement in year-round, physical activities",
"         </li>",
"         <li>",
"          Support continued family activity once a week and/or family support of adolescent's physical activity program",
"         </li>",
"         <li>",
"          Endorse appropriate safety equipment relative to each sport",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        18-21 y",
"       </td>",
"       <td>",
"        Moderate to vigorous physical activity* every day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limit leisure time TV/video/computer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Supportive actions:",
"        </em>",
"        <br/>",
"        <ul>",
"         <li>",
"          Support goal of 1 h/d of moderate to vigorous daily activity with vigorous intense physical activity on 3 d/wk",
"         </li>",
"         <li>",
"          Recommend that combined leisure screen time not exceed 2 h/d",
"         </li>",
"         <li>",
"          Activity and screen time history at health supervision visits",
"         </li>",
"         <li>",
"          Encourage involvement in year-round, lifelong physical activities",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     * Examples of moderate to vigorous physical activities are jogging or playing baseball.",
"     <br>",
"      &Delta; Examples of vigorous physical activities are running, playing singles tennis, or playing soccer.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report.",
"     <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/summary.htm#chap5\" target=\"_blank\">",
"      file://www.nhlbi.nih.gov/guidelines/cvd_ped/summary.htm#chap5",
"     </a>",
"     (Accessed on January 3, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_10_20653=[""].join("\n");
var outline_f20_10_20653=null;
var title_f20_10_20654="HAI reliability";
var content_f20_10_20654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78265%7EGAST%2F65481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78265%7EGAST%2F65481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraobserver reliability in HAI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 263px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Duplicate readings by the same observer demonstrate good concordance of the histologic activity index (HAI) in sixteen liver biopsies from five patients with chronic hepatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Knodell RG, Ishak KG, Black WC, et al. Hepatology 1981; 1:431.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Correlation of HAI with conventional interpretation of liver biopsy specimens",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 306px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Correlation between the histologic activity index (HAI) and conventional interpretation of liver biopsy specimens from patients with chronic hepatitis. The mean HAI score increased with increasing severity as assessed by conventional qualitative diagnosis.",
"    <div class=\"footnotes\">",
"     CPH: chronic persistent hepatitis; CAH: chronic active hepatitis; and MLH: multilobular necrosis.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Knodell RG, Ishak KG, Black WC, et al. Hepatology 1981; 1:431.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_10_20654=[""].join("\n");
var outline_f20_10_20654=null;
var title_f20_10_20655="Towel stretch";
var content_f20_10_20655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Towel stretch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Take a 3 foot long towel, grasp it with both hands, and hold it in the horizontal position. Use the upper, good arm, to pull the affected arm toward the lower back. This can be repeated with the towel at a 45&deg; angle. Perform sets of 10 to 20 stretches at each session.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_10_20655=[""].join("\n");
var outline_f20_10_20655=null;
